Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 54
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

Insights from Learning Analytics for Hands-On Cloud Computing Labs in AWS

  • Moltó, Germán|||0000-0002-8049-253X
  • Segrelles Quilis, José Damián|||0000-0001-5698-7965
  • Naranjo-Delgado, Diana María
[EN] Cloud computing instruction requires hands-on experience with a myriad of distributed computing services from a public cloud provider. Tracking the progress of the students, especially for online courses, requires one to automatically gather evidence and produce learning analytics in order to further determine the behavior and performance of students. With this aim, this paper describes the experience from an online course in cloud computing with Amazon Web Services on the creation of an open-source data processing tool to systematically obtain learning analytics related to the hands-on activities carried out throughout the course. These data, combined with the data obtained from the learning management system, have allowed the better characterization of the behavior of students in the course. Insights from a population of more than 420 online students through three academic years have been assessed, the dataset has been released for increased reproducibility. The results corroborate that course length has an impact on online students dropout. In addition, a gender analysis pointed out that there are no statistically significant differences in the final marks between genders, but women show an increased degree of commitment with the activities planned in the course., This research was funded by the Spanish "Ministerio de Economia, Industria y Competitividad through grant number TIN2016-79951-R (BigCLOE)", the "Vicerrectorado de Estudios, Calidad y Acreditacion" of the Universitat Politecnica de Valencia (UPV) to develop the PIME B29 and PIME/19-20/166, and by the Conselleria d'Innovacio, Universitat, Ciencia i Societat Digital for the project "CloudSTEM" with reference number AICO/2019/313.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

A Cloud framework for Problem-Based Learning on Grid Computing

  • Segrelles Quilis, José Damián|||0000-0001-5698-7965
  • Moltó, Germán|||0000-0002-8049-253X
  • Blanquer Espert, Ignacio|||0000-0003-1692-8922
[EN] Training on Grid technologies has traditionally used existing Grid infrastructures to implement the hands-on education activities. However, these infrastructures are insufficient to develop all training skills as they can only be employed for the development of Grid applications, and they are limited for learning the management and configuration of Grid resources. The paper presents a set of educational activities grouped on a Project Based Learning (PBL) framework for training on Grid technologies. A Cloud-based tool has been implemented to provide Grid infrastructures as a Service on the cloud, with enhanced scalability and administration capabilities. The PBL has achieved a high impact in the teaching-learning process, addressing the training in all the necessary skills and efficiently providing Grid infrastructure resources on public clouds at a moderate cost. Finally, we evaluated the students' opinion on the activities achieving a very satisfactory result and a reasonable balance on the complexity of the PBL stages. (C) 2021 Elsevier Inc. All rights reserved., The authors wish to thank the financial support received from Vicerrectorado de Estudios, Calidad y Acreditacion of the Universitat Politecnica de Valencia to develop the PIME project with reference B29, and to the Conselleria d'Educacio, Investigacio, Cultura i Esport de la Generalitat Valenciana for the project with reference number AICO/2019/303
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Microbiota and lung cancer. Opportunities and challenges for improving immunotherapy efficacy

  • Ocáriz, Maitane
  • Cruellas, Mara
  • Gascón, Marta
  • Lastra, Rodrigo
  • Martínez-Lostao, Luis
  • Ramírez-Labrada, Ariel
  • Paño, José Ramón
  • Sesma, Andrea
  • Torres-Ramón, Irene
  • Yubero, Alfonso
  • Pardo, Julián
  • Isla, Dolores
  • Gálvez Buerba, Eva Mª
The advances in molecular biology and the emergence of Next Generation Sequencing (NGS) have revealed that microbiome composition is closely related with health and disease, including cancer. This relationship affects different levels of cancer such as development, progression, and response to treatment including immunotherapy. The efficacy of immune checkpoint inhibitors (ICIs) may be influenced by the concomitant use of antibiotics before, during or shortly after treatment with ICIs. Nevertheless, the linking mechanism between microbiote, host immunity and cancer is not clear and the role of microbiota manipulation and analyses in cancer management has not been clinically validated yet. Regarding the use of microbiome as biomarker to predict ICI efficacy it has been recently shown that the use of biochemical serum markers to monitor intestinal permeability and loss of barrier integrity, like citrulline, could be useful to monitor microbiota changes and predict ICI efficacy. There are still many unknowns about the role of these components, their relationship with the microbiota, with the use of antibiotics and the response to immunotherapy. The next challenge in microbiome research will be to identify individual microbial species that causally affect lung cancer phenotypes and response to ICI and disentangle the underlying mechanisms. Thus, further analyses in patients with lung cancer receiving treatment with ICIs and its correlation with the composition of the microbiota in different organs including the respiratory tract, peripheral blood and intestinal tract could be useful to predict the efficacy of ICIs and its modulation with antibiotic use., JP reported research funding from BMS and Gilead and speaker honoraria from Gilead and Pfizer. EG reported research funding from BMS and Gilead. JP and EG were funded by FEDER (Fondo Europeo de Desarrollo Regional, Gobierno de Aragón (Group B29_17R), Ministerio de Ciencia, Innovación e Universidades (MCNU), Agencia Estatal de Investigación (SAF2017-83120-C2- 1-R), Fundacion Inocente Inocente, ASPANOA and Carrera de la Mujer de Monzón. JP was supported by ARAID Foundation. DI reported consultation honoraria from AbbVie, Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann-La Roche, Merck, MSD, Novartis, Pierre Fabre, Pfizer, and Takeda. DI reported speaker honoraria from Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly Oncology, F. Hoffmann-La Roche, MSD, Novartis, Pierre Fabre, and Pfizer. DI reported research grant from AstraZeneca, BMS, F. Hoffmann-La Roche, MSD, and Pierre Fabre., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Adoptive NK cell transfer as a treatment in colorectal cancer patients: analyses of tumour cell determinants correlating with efficacy in vitro and in vivo

  • Lanuza, Pilar M.
  • Alonso, M. Henar
  • Hidalgo, Sandra
  • Uranga Murillo, Iratxe
  • García-Mulero, Sandra
  • Arnau, Raquel
  • Santos Vivas, Cristina
  • Sanjuan, Xavier
  • Santiago, Llipsy
  • Comas, Laura
  • Redrado, Sergio
  • Pazo-Cid, Roberto
  • Agustín Ferrández, M. J.
  • Jaime Sánchez, Paula
  • Pesini, Cecilia
  • Gálvez Buerba, Eva Mª
  • Ramírez-Labrada, Ariel
  • Arias, Maykel
  • Sanz-Pamplona, Rebeca
  • Pardo, Julián
6 figures., [Background]: Colorectal cancer (CRC) is a heterogeneous disease with variable mutational profile and tumour microenvironment composition that influence tumour progression and response to treatment. While chemoresistant and poorly immunogenic CRC remains a challenge, the development of new strategies guided by biomarkers could help stratify and treat patients. Allogeneic NK cell transfer emerges as an alternative against chemoresistant and poorly immunogenic CRC., [Methods]: NK cell-related immunological markers were analysed by transcriptomics and immunohistochemistry in human CRC samples and correlated with tumour progression and overall survival. The anti-tumour ability of expanded allogeneic NK cells using a protocol combining cytokines and feeder cells was analysed in vitro and in vivo and correlated with CRC mutational status and the expression of ligands for immune checkpoint (IC) receptors regulating NK cell activity., [Results]: HLA-I downmodulation and NK cell infiltration correlated with better overall survival in patients with a low-stage (II) microsatellite instability-high (MSI-H) CRC, suggesting a role of HLA-I as a prognosis biomarker and a potential benefit of NK cell immunotherapy. Activated allogeneic NK cells were able to eliminate CRC cultures without PD-1 and TIM-3 restriction but were affected by HLA-I expression. In vivo experiments confirmed the efficacy of the therapy against both HLA+ and HLA− CRC cell lines. Concomitant administration of pembrolizumab failed to improve tumour control., [Conclusions]: Our results reveal an immunological profile of CRC tumours in which immunogenicity (MSI-H) and immune evasion mechanisms (HLA downmodulation) favour NK cell immunosurveillance at early disease stages. Accordingly, we have shown that allogeneic NK cell therapy can target tumours expressing mutations conferring poor prognosis regardless of the expression of T cell-related inhibitory IC ligands. Overall, this study provides a rationale for a new potential basis for CRC stratification and NK cell-based therapy., Work in the JP laboratory is funded by ASPANOA, CIBER (CB 2021; Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación and Union Europea.NextGenerationEU), Fundacion Inocente, Carrera de la Mujer Monzón, FEDER/Gobierno de Aragón (Group B29_17R), and Ministerio de Ciencia, Innovación e Universidades (MCNU), Agencia Estatal de Investigación (SAF2017‐83120‐C2‐1‐R and PID2020-113963RB-I00). Predoctoral grants/contracts from Gobierno de Aragon (IU-M and JP) are supported by ARAID Foundation. EG is funded by Ministerio de Ciencia, Innovación y Universidades (MCNU), and Agencia Estatal de Investigación (PID2020-113963RB-I00). MA and LS are funded by Postdoctoral Juan de la Cierva Contract. SR, LC, SH, and IU-M are funded by predoctoral contracts from Aragon Government. PL is funded by FPU predoctoral grants from Ministerio de Ciencia, Innovación e Universidades. Work at the Catalan Institute of Oncology is funded by the entity, the Instituto de Salud Carlos III and Ministerio de Economia y Competitividad, and co-funded by FEDER funds—a way to build Europe (PI20/00767), CIBERESP (grant CB07/02/2005), H2020 grant MoTriColor, and the Agency for Management of University and Research Grants (AGAUR) of the Catalan Government grant 2017SGR723. This work is supported by COST Action CA17118., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

PD-1 is expressed in cytotoxic granules of NK cells and rapidly mobilized to the cell membrane following recognition of tumor cells

  • Pesini, Cecilia
  • Hidalgo, Sandra
  • Arias, Maykel
  • Santiago, Llipsy
  • Calvo, Carlota
  • Ocáriz, Maitane
  • Isla, Dolores
  • Lanuza, Pilar M.
  • Agustín Ferrández, M. J.
  • Gálvez Buerba, Eva Mª
  • Ramírez-Labrada, Ariel
  • Pardo, Julián
5 figures.-- Supplementary information available., The contribution of the T cell-related inhibitory checkpoint PD-1 to the regulation of NK cell activity is still not clear with contradictory results concerning its expression and role in the modulation of NK cell cytotoxicity. We provide novel key findings on the mechanism involved in the regulation of PD-1 expression on NK cell membrane and its functional consequences for the elimination of cancer cells. In contrast to freshly isolated NK cells from cancer patients, those from healthy donors did not express PD-1 on the cell membrane. However, when healthy NK cells were incubated with tumor target cells, membrane PD-1 expression increased, concurrent with the CD107a surface mobilization. This finding suggested that PD-1 was translocated to the cell membrane during NK cell degranulation after contact with target cells. Indeed, cytosolic PD-1 was expressed in freshly-isolated-NK cells and partly co-localized with CD107a and GzmB, confirming that membrane PD-1 corresponded to a pool of preformed PD-1. Moreover, NK cells that had mobilized PD-1 to the cell membrane presented a significantly reduced antitumor activity on PD-L1-expressing-tumor cells in vitro and in vivo, which was partly reversed by using anti-PD-1 blocking antibodies. Our results indicate that NK cells from healthy individuals express cytotoxic granule-associated PD-1, which is rapidly mobilized to the cell membrane after interaction with tumor target cells. This novel finding helps to understand how PD-1 expression is regulated on NK cell membrane and the functional consequences of this expression during the elimination of tumor cells, which will help to design more efficient NK cell-based cancer immunotherapies., Work in the JP laboratory is funded by FEDER (Fondo Europeo de Desarrollo Regional), Gobierno de Aragón (Group B29_20R), Ministerio de Ciencia, Innovación y Universidades (MCUN), Agencia Estatal de Investigación (SAF2017-83120-C2-1-R; PID2020-113963RBI00), Fundación Inocente Inocente, ASPANOA, and Carrera de la Mujer de Monzón. Postdoctoral Juan de la Cierva Contract (MA and LS) and Predoctoral Grant from AECC (CP). JP is supported by ARAID Foundation; Fundación Agencia Aragonesa para la investigación y el Desarrollo; Fundación Científica Asociación Española Contra el Cáncer., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Perforin and Granzyme B Expressed by Murine Myeloid-Derived Suppressor Cells: A Study on Their Role in Outgrowth of Cancer Cells

  • Dufait, Inès
  • Pardo, Julián
  • Escors, David
  • De Vlaeminck, Yannick
  • Jiang, Heng
  • Keyaerts, Marleen
  • De Ridder, Mark
  • Breckpot, Karine
A wide-range of myeloid-derived suppressor cell (MDSC)-mediated immune suppressive functions has previously been described. Nevertheless, potential novel mechanisms by which MDSCs aid tumor progression are, in all likelihood, still unrecognized. Next to its well-known expression in natural killer cells and cytotoxic T lymphocytes (CTLs), granzyme B (GzmB) expression has been found in different cell types. In an MDSC culture model, we demonstrated perforin and GzmB expression. Furthermore, similar observations were made in MDSCs isolated from tumor-bearing mice. Even in MDSCs from humans, GzmB expression was demonstrated. Of note, B16F10 melanoma cells co-cultured with perforin/GzmB knock out mice (KO) MDSCs displayed a remarkable decrease in invasive potential. B16F10 melanoma cells co-injected with KO MDSCs, displayed a significant slower growth curve compared to tumor cells co-injected with wild type (WT) MDSCs. In vivo absence of perforin/GzmB in MDSCs resulted in a higher number of CD8+ T-cells. Despite this change in favor of CD8+ T-cell infiltration, we observed low interferon-¿ (IFN-¿) and high programmed death-ligand 1 (PD-L1) expression, suggesting that other immunosuppressive mechanisms render these CD8+ T-cells dysfunctional. Taken together, our results suggest that GzmB expression in MDSCs is another means to promote tumor growth and warrants further investigation to unravel the exact underlying mechanism.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Cell death induced by cytotoxic CD8 + T cells is immunogenic and primes caspase-3-dependent spread immunity against endogenous tumor antigens

  • Jaime-Sanchez, Paula
  • Uranga-Murillo, Iratxe
  • Aguilo, Nacho
  • Khouili, Sofía C.
  • Arias, Maykel A.
  • Sancho, David
  • Pardo, Julián
Background Elimination of cancer cells by some stimuli like chemotherapy and radiotherapy activates anticancer immunity after the generation of damage-associated molecular patterns, a process recently named immunogenic cell death (ICD). Despite the recent advances in cancer immunotherapy, very little is known about the immunological consequences of cell death activated by cytotoxic CD8 + T (Tc) cells on cancer cells, that is, if Tc cells induce ICD on cancer cells and the molecular mechanisms involved. Methods ICD induced by Tc cells on EL4 cells was analyzed in tumor by vaccinating mice with EL4 cells killed in vitro or in vivo by Ag-specific Tc cells. EL4 cells and mutants thereof overexpressing Bcl-X L or a dominant negative mutant of caspase-3 and wild-type mice, as well as mice depleted of Tc cells and mice deficient in perforin, TLR4 and BATF3 were used. Ex vivo cytotoxicity of spleen cells from immunized mice was analyzed by flow cytometry. Expression of ICD signals (calreticulin, HMGB1 and interleukin (IL)-1ß) was analyzed by flow cytometry and ELISA. Results Mice immunized with EL4.gp33 cells killed in vitro or in vivo by gp33-specific Tc cells were protected from parental EL4 tumor development. This result was confirmed in vivo by using ovalbumin (OVA) as another surrogate antigen. Perforin and TLR4 and BATF3-dependent type 1 conventional dendritic cells (cDC1s) were required for protection against tumor development, indicating cross-priming of Tc cells against endogenous EL4 tumor antigens. Tc cells induced ICD signals in EL4 cells. Notably, ICD of EL4 cells was dependent on caspase-3 activity, with reduced antitumor immunity generated by caspase-3-deficient EL4 cells. In contrast, overexpression of Bcl-X L in EL4 cells had no effect on induction of Tc cell antitumor response and protection. Conclusions Elimination of tumor cells by Ag-specific Tc cells is immunogenic and protects against tumor development by generating new Tc cells against EL4 endogenous antigens. This finding helps to explain the enhanced efficacy of T cell-dependent immunotherapy and provide a molecular basis to explain the epitope spread phenomenon observed during vaccination and chimeric antigen receptor (CAR)-T cell therapy. In addition, they suggest that caspase-3 activity in the tumor may be used as a biomarker to predict cancer recurrence during T cell-dependent immunotherapies.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Reseña (Review)

Intratumoral versus Circulating Lymphoid Cells as Predictive Biomarkers in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Is the Easiest Path the Best One?

  • Gascón, Marta
  • Isla, Dolores
  • Cruellas, Mara
  • Gálvez, Eva M.
  • Lastra, Rodrigo
  • Ocáriz, Maitane
  • Paño, José Ramón
  • Ramírez, Ariel
  • Sesma, Andrea
  • Torres-Ramón, Irene
  • Yubero, Alfonso
  • Pardo, Julián
  • Martínez-Lostao, Luis
The molecular and cell determinants that modulate immune checkpoint (ICI) efficacy in lung cancer are still not well understood. However, there is a necessity to select those patients that will most benefit from these new treatments. Recent studies suggest the presence and/or the relative balance of specific lymphoid cells in the tumor microenvironment (TEM) including the T cell (activated, memory, and regulatory) and NK cell (CD56dim/bright) subsets, and correlate with a better response to ICI. The analyses of these cell subsets in peripheral blood, as a more accessible and homogeneous sample, might facilitate clinical decisions concerning fast prediction of ICI efficacy. Despite recent studies suggesting that lymphoid circulating cells might correlate with ICI efficacy and toxicity, more analyses and investigation are required to confirm if circulating lymphoid cells are a relevant picture of the lung TME and could be instrumental as ICI response biomarkers. This short review is aimed to discuss the recent advances in this fast-growing field.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

The Multifaceted Function of Granzymes in Sepsis: Some Facts and a Lot to Discover

  • Garzon-Tituaña, M.
  • Arias, M.A.
  • Sierra-Monzon, J.L.
  • Morte-Romea, E.
  • Santiago, L.
  • Ramirez-Labrada, A.
  • Martinez-Lostao, L.
  • Paño-Pardo, J.R.
  • Galvez, E.M.
  • Pardo, J.
Sepsis is a serious global health problem. In addition to a high incidence, this syndrome has a high mortality and is responsible for huge health expenditure. The pathophysiology of sepsis is very complex and it is not well-understood yet. However, it is widely accepted that the initial phase of sepsis is characterized by a hyperinflammatory response while the late phase is characterized by immunosuppression and immune anergy, increasing the risk of secondary infections. Granzymes (Gzms) are a family of serine proteases classified according to their cleavage specificity. Traditionally, it was assumed that all Gzms acted as cytotoxic proteases. However, recent evidence suggests that GzmB is the one with the greatest cytotoxic capacity, while the cytotoxicity of others such as GzmA and GzmK is not clear. Recent studies have found that GzmA, GzmB, GzmK, and GzmM act as pro-inflammatory mediators. Specially, solid evidences show that GzmA and GzmK function as extracellular proteases that regulate the inflammatory response irrespectively of its ability to induce cell death. Indeed, studies in animal models indicate that GzmA is involved in the cytokine release syndrome characteristic of sepsis. Moreover, the GZM family also could regulate other biological processes involved in sepsis pathophysiology like the coagulation cascade, platelet function, endothelial barrier permeability, and, in addition, could be involved in the immunosuppressive stage of sepsis. In this review, we provide a comprehensive overview on the contribution of these novel functions of Gzms to sepsis and the new therapeutic opportunities emerging from targeting these proteases for the treatment of this serious health problem.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Granzyme A-producing T helper cells are critical for acute graft-versus-host disease

  • Park, S.
  • Griesenauer, B.
  • Jiang, H.
  • Adom, D.
  • Mehrpouya-Bahrami, P.
  • Chakravorty, S.
  • Kazemian, M.
  • Imam, T.
  • Srivastava, R.
  • Hayes, T.A.
  • Pardo, J.
  • Janga, S.C.
  • Paczesny, S.
  • Kaplan, M.H.
  • Olson, M.R.
Acute graft-versus-host disease (aGVHD) can occur after hematopoietic cell transplant in patients undergoing treatment for hematological malignancies or inborn errors. Although CD4+ T helper (Th) cells play a major role in aGVHD, the mechanisms by which they contribute, particularly within the intestines, have remained elusive. We have identified a potentially novel subset of Th cells that accumulated in the intestines and produced the serine protease granzyme A (GrA). GrA+ Th cells were distinct from other Th lineages and exhibited a noncytolytic phenotype. In vitro, GrA+ Th cells differentiated in the presence of IL-4, IL-6, and IL-21 and were transcriptionally unique from cells cultured with either IL-4 or the IL-6/IL-21 combination alone. In vivo, both STAT3 and STAT6 were required for GrA+ Th cell differentiation and played roles in maintenance of the lineage identity. Importantly, GrA+ Th cells promoted aGVHD-associated morbidity and mortality and contributed to crypt destruction within intestines but were not required for the beneficial graft-versus-leukemia effect. Our data indicate that GrA+ Th cells represent a distinct Th subset and are critical mediators of aGVHD.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Recalling the Biological Significance of Immune Checkpoints on NK Cells: A Chance to Overcome LAG3, PD1, and CTLA4 Inhibitory Pathways by Adoptive NK Cell Transfer?

  • Lanuza, Pilar M.
  • Pesini, Cecilia
  • Arias, Maykel A
  • Calvo, Carlota
  • Ramirez-Labrada, Ariel
  • Pardo, Julián
Immune checkpoint receptors (IC) positively or negatively regulate the activation of the host immune response, preventing unwanted reactions against self-healthy tissues. In recent years the term IC has been mainly used for the inhibitory ICs, which are critical to control Natural Killer (NK) and Cytotoxic CD8(+) T cells due to its high cytotoxic potential. Due to the different nature of the signals that regulate T and NK cell activation, specific ICs have been described that mainly regulate either NK cell or T cell activity. Thus, strategies to modulate NK cell activity are raising as promising tools to treat tumors that do not respond to T cell-based immunotherapies. NK cell activation is mainly regulated by ICs and receptors from the KIR, NKG2 and NCRs families and the contribution of T cell-related ICs is less clear. Recently, NK cells have emerged as contributors to the effect of inhibitors of T cell-related ICs like CTLA4, LAG3 or the PD1/PD-L1 axes in cancer patients, suggesting that these ICs also regulate the activity of NK cells under pathological conditions. Strikingly, in contrast to NK cells from cancer patients, the level of expression of these ICs is low on most subsets of freshly isolated and in vitro activated NK cells from healthy patients, suggesting that they do not control NK cell tolerance and thus, do not act as conventional ICs under non-pathological conditions. The low level of expression of T cell-related ICs in "healthy" NK cells suggest that they should not be restricted to the detrimental effects of these inhibitory mechanisms in the cancer microenvironment. After a brief introduction of the regulatory mechanisms that control NK cell anti-tumoral activity and the conventional ICs controlling NK cell tolerance, we will critically discuss the potential role of T cell-related ICs in the control of NK cell activity under both physiological and pathological (cancer) conditions. This discussion will allow to comprehensively describe the chances and potential limitations of using allogeneic NK cells isolated from a healthy environment to overcome immune subversion by T cell-related ICs and to improve the efficacy of IC inhibitors (ICIs) in a safer way.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Extracellular granzyme A promotes colorectal cancer development by enhancing gut inflammation

  • Santiago, L.
  • Castro, Marta
  • Sanz-Pamplona, Rebeca
  • Garzón, Marcela
  • Ramírez-Labrada A.
  • Tapia E.
  • Moreno V.
  • Layunta, E.
  • Gil-Gómez, G.
  • Garrido, M.
  • Peña R.
  • Lanuza, P.M.
  • Comas L.
  • Jaime-Sánchez, P.
  • Uranga-Murillo, I.
  • del Campo, R.
  • Pelegrín, P.
  • Camerer, E.
  • Martínez-Lostao, L.
  • Muñoz, G.
  • Uranga, J.A.
  • Alcalde, A.
  • Galvez, E.M.
  • Ferrández, A.
  • Bird, P.I.
  • Metkar, S.
  • Arias, M.A.
  • Pardo, J.
If not properly regulated, the inflammatory immune response can promote carcinogenesis, as evident in colorectal cancer (CRC). Aiming to gain mechanistic insight into the link between inflammation and CRC, we perform transcriptomics analysis of human CRC, identifying a strong correlation between expression of the serine protease granzyme A (GzmA) and inflammation. In a dextran sodium sulfate and azoxymethane (DSS/AOM) mouse model, deficiency and pharmacological inhibition of extracellular GzmA both attenuate gut inflammation and prevent CRC development, including the initial steps of cell transformation and epithelial-to-mesenchymal transition. Mechanistically, extracellular GzmA induces NF-κB-dependent IL-6 production in macrophages, which in turn promotes STAT3 activation in cultured CRC cells. Accordingly, colon tissues from DSS/AOM-treated, GzmA-deficient animals present reduced levels of pSTAT3. By identifying GzmA as a proinflammatory protease that promotes CRC development, these findings provide information on mechanisms that link immune cell infiltration to cancer progression and present GzmA as a therapeutic target for CRC.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Reseña (Review)

Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy

  • Ocáriz-Díez, M.
  • Cruellas, M.
  • Gascón, M.
  • Lastra, R.
  • Martínez-Lostao, L.
  • Ramírez-Labrada, A.
  • Paño, J.R.
  • Sesma, A.
  • Torres, I.
  • Yubero, A.
  • Pardo, J.
  • Isla, D.
  • Gálvez, E.M.
The advances in molecular biology and the emergence of Next Generation Sequencing (NGS) have revealed that microbiome composition is closely related with health and disease, including cancer. This relationship affects different levels of cancer such as development, progression, and response to treatment including immunotherapy. The efficacy of immune checkpoint inhibitors (ICIs) may be influenced by the concomitant use of antibiotics before, during or shortly after treatment with ICIs. Nevertheless, the linking mechanism between microbiote, host immunity and cancer is not clear and the role of microbiota manipulation and analyses in cancer management has not been clinically validated yet. Regarding the use of microbiome as biomarker to predict ICI efficacy it has been recently shown that the use of biochemical serum markers to monitor intestinal permeability and loss of barrier integrity, like citrulline, could be useful to monitor microbiota changes and predict ICI efficacy. There are still many unknowns about the role of these components, their relationship with the microbiota, with the use of antibiotics and the response to immunotherapy. The next challenge in microbiome research will be to identify individual microbial species that causally affect lung cancer phenotypes and response to ICI and disentangle the underlying mechanisms. Thus, further analyses in patients with lung cancer receiving treatment with ICIs and its correlation with the composition of the microbiota in different organs including the respiratory tract, peripheral blood and intestinal tract could be useful to predict the efficacy of ICIs and its modulation with antibiotic use.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

SARS-CoV-2 vaccines: Inactivation by gamma irradiation for T and B cell immunity

  • Mullbacher, A.
  • Pardo, J.
  • Furuya, Y.
Despite accumulating preclinical data demonstrating a crucial role of cytotoxic T cell immunity during viral infections, ongoing efforts on developing COVID-19 vaccines are mostly focused on antibodies. In this commentary article, we discuss potential benefits of cytotoxic T cells in providing long-term protection against COVID-19. Further, we propose that gamma-ray irradiation, which is a previously tested inactivation method, may be utilized to prepare an experimental COVID-19 vaccine that can provide balanced immunity involving both B and T cells.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

In Vitro and In Vivo Antibacterial Activity of Gliotoxin Alone and in Combination with Antibiotics against Staphylococcus aureus

  • Esteban, P.
  • Redrado, S.
  • Comas, L.
  • Domingo, M.P.
  • Millán-Lou, M.I.
  • Seral, C.
  • Algarate, S.
  • Lopez, C.
  • Rezusta, A.
  • Pardo, J.
  • Arias, M.
  • Galvez, E.M.
Multidrug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) is one of the major causes of hospital-acquired and community infections and pose a challenge to the human health care system. Therefore, it is important to find new drugs that show activity against these bacteria, both in monotherapy and in combination with other antimicrobial drugs. Gliotoxin (GT) is a mycotoxin produced by Aspergillus fumigatus and other fungi of the Aspergillus genus. Some evidence suggests that GT shows antimicrobial activity against S. aureus in vitro, albeit its efficacy against multidrug-resistant strains such asMRSA or vancomycin-intermediate S. aureus (VISA) strainsis not known. This work aimedto evaluate the antibiotic efficacy of GT as monotherapy or in combination with other therapeutics against MRSA in vitro and in vivo using a Caenorhabditis elegans infection model.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2

  • Santiago, Llipsy
  • Uranga-Murillo, Iratxe
  • Arias, Maykel
  • González-Ramírez, Andrés M.
  • Macías-León, Javier
  • Moreo, Eduardo
  • Redrado, Sergio
  • García-García, Ana
  • Taleb, Víctor
  • Lira-Navarrete, Erandi
  • Hurtado-Guerrero, Ramón
  • Aguilo, Nacho
  • del Mar Encabo-Berzosa, Maria
  • Hidalgo, Sandra
  • Galvez, Eva M.
  • Ramirez-Labrada, Ariel
  • de Miguel, Diego
  • Benito, Rafael
  • Miranda, Patricia
  • Fernández, Antonio
  • Domingo, José M.
  • Serrano, Laura
  • Yuste, Cristina
  • Villanueva-Saz, Sergio
  • Paño-Pardo, José R.
  • Pardo, Julián
Several hundred millions of people have been diagnosed of coronavirus disease 2019 (COVID-19), causing millions of deaths and a high socioeconomic burden. SARS-CoV-2, the causative agent of COVID-19, induces both specific T- and B-cell responses, being antibodies against the virus detected a few days after infection. Passive immunization with hyperimmune plasma from convalescent patients has been proposed as a potentially useful treatment for COVID-19. Using an in-house quantitative ELISA test, we found that plasma from 177 convalescent donors contained IgG antibodies specific to the spike receptor-binding domain (RBD) of SARS-CoV-2, although at very different concentrations which correlated with previous disease severity and gender. Anti-RBD IgG plasma concentrations significantly correlated with the plasma viral neutralizing activity (VN) against SARS-CoV-2 in vitro. Similar results were found using an independent cohort of serum from 168 convalescent health workers. These results validate an in-house RBD IgG ELISA test in a large cohort of COVID-19 convalescent patients and indicate that plasma from all convalescent donors does not contain a high enough amount of anti-SARS-CoV-2-RBD neutralizing IgG to prevent SARS-CoV-2 infection in vitro. The use of quantitative anti-RBD IgG detection systems might help to predict the efficacy of the passive immunization using plasma from patients recovered from SARS-CoV-2.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Granzyme A inhibition reduces inflammation and increases survival during abdominal sepsis

  • Garzon-Tituana, M
  • Sierra-Monzon, JL
  • Comas, L
  • Santiago, L
  • Khaliulina-Ushakova, T
  • Uranga-Murillo, I
  • Ramirez-Labrada, A
  • Tapia, E
  • Morte-Romea, E
  • Algarate, S
  • Couty, L
  • Camerer, E
  • Bird, PI
  • Seral, C
  • Luque, P
  • Pano-Pardo, JR
  • Galvez, EM
  • Pardo, J
  • Arias, M
Aims: Peritonitis is one of the most common causes of sepsis, a serious syndrome characterized by a dysregulated systemic inflammatory response. Recent evidence suggests that Granzyme A (GzmA), a serine protease mainly expressed by NK and T cells, could act as a proinflammatory mediator and could play an important role in the pathogenesis of sepsis. This work aims to analyze the role and the therapeutic potential of GzmA in the pathogenesis of peritoneal sepsis. Methods: The level of extracellular GzmA as well as GzmA activity were analyzed in serum from healthy volunteers and patients with confirmed peritonitis and were correlated with the Sequential Organ Failure Assessment (SOFA) score. Peritonitis was induced in C57BI/6 (WT) and GzmA(-/-) mice by cecal ligation and puncture (CLP). Mice were treated intraperitoneally with antibiotics alone or in combination serpinb6b, a specific GzmA inhibitor, for 5 days. Mouse survival was monitored during 14 days, levels of some proinflammatory cytokines were measured in serum and bacterial load and diversity was analyzed in blood and spleen at different times. Results: Clinically, elevated GzmA was observed in serum from patients with abdominal sepsis suggesting that GzmA plays an important role in this pathology. In the CLP model GzmA deficient mice, or WT mice treated with an extracellular GzmA inhibitor, showed increased survival, which correlated with a reduction in proinflammatory markers in both serum and peritoneal lavage fluid. GzmA deficiency did not influence bacterial load in blood and spleen and GzmA did not affect bacterial replication in macrophages in vitro, indicating that GzmA has no role in bacterial control. Analysis of GzmA in lymphoid cells following CLP showed that it was mainly expressed by NK cells. Mechanistically, we found that extracellular active GzmA acts as a proinflammatory mediator in macrophages by inducing the TLR4-dependent expression of IL-6 and TNF alpha. Conclusions: Our findings implicate GzmA as a key regulator of the inflammatory response during abdominal sepsis and provide solid evidences about its therapeutic potential for the treatment of this severe pathology.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Sars-cov-2 seroprevalence in household domestic ferrets (Mustela putorius furo)

  • Giner, Jacobo
  • Villanueva-Saz, Sergio
  • Tobajas, Ana Pilar
  • Pérez, María Dolores
  • González, Ana
  • Verde, Maite
  • Yzuel, Andrés
  • García-García, Ana
  • Taleb, Víctor
  • Lira-Navarrete, Erandi
  • Hurtado-Guerrero, Ramón
  • Pardo, Julián
  • Santiago, Llipsy
  • Paño, José Ramón
  • Ruíz, Héctor
  • Lacasta, Delia
  • Fernández, Antonio
Animal infections with SARS-CoV-2 have been reported in different countries and several animal species have been proven to be susceptible to infection with SARS-CoV-2 both naturally and by experimental infection. Moreover, infections under natural conditions in more than 20 mink farms have been reported where humans could have been the source of infection for minks. However, little information is available about the susceptibility of pet animals under natural conditions and currently there is no SARS-CoV-2 epidemiological assessment occurrence in household ferrets. In this study, the presence of SARS-CoV-2 antibodies was evaluated in serum samples obtained from 127 household ferrets (Mustela putorius furo) in the Province of Valencia (Spain). Two ferrets tested positive to SARS-CoV-2 (1.57%) by in-house enzyme-linked immunosorbent assay based on receptor binding domain (RBD) of Spike antigen. Furthermore, anti- RBD SARS-CoV-2 antibodies persisted at detectable levels in a seropositive SARS-CoV-2 domestic ferret beyond 129 days since the first time antibodies were detected. This study reports for the first time the evidence of household pet ferrets exposure to SARS-CoV-2 in Spain to date.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Otros (Other)

TRAIL and Cancer Immunotherapy: Take a Walk on the Short Side

  • de Miguel, D.
  • Pardo, J.
Recent work shows that TRAILshort, a membrane-bound short form of TRAIL, is expressed by human cancer cells and protects them from TRAIL-induced cell death. AmAbthat selectively targets TRAILshort enhances cancer susceptibility to TRAIL and increases the efficacy of autologous CD8(+) T cells in ex vivo primary tumors.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Integrated analysis of circulating immune cellular and soluble mediators reveals specific COVID19 signatures at hospital admission with utility for prediction of clinical outcomes

  • Uranga-Murillo, Iratxe
  • Morte, Elena
  • Hidalgo, Sandra
  • Pesini, Cecilia
  • Garcia-Mulero, Sandra
  • Sierra, Jose L.
  • Santiago, Llipsy
  • Arias, Maykel
  • De Miguel, Diego
  • Encabo-Berzosa, Maria Del Mar
  • Gracia-Tello, Borja
  • Sanz-Pamplona, Rebeca
  • Martinez-Lostao, Luis
  • Galvez, Eva M.
  • Paño-Pardo, Jose R.
  • Ramirez-Labrada, Ariel
  • Pardo, Julian
Coronavirus disease 2019 (COVID19), caused by SARS-CoV-2, is a complex disease, with a variety of clinical manifestations ranging from asymptomatic infection or mild cold-like symptoms to more severe cases requiring hospitalization and critical care. The most severe presentations seem to be related with a delayed, deregulated immune response leading to exacerbated inflammation and organ damage with close similarities to sepsis. Methods: In order to improve the understanding on the relation between host immune response and disease course, we have studied the differences in the cellular (monocytes, CD8+ T and NK cells) and soluble (cytokines, chemokines and immunoregulatory ligands) immune response in blood between Healthy Donors (HD), COVID19 and a group of patients with non-COVID19 respiratory tract infections (NON-COV-RTI). In addition, the immune response profile has been analyzed in COVID19 patients according to disease severity. Results: In comparison to HDs and patients with NON-COV-RTI, COVID19 patients show a heterogeneous immune response with the presence of both activated and exhausted CD8+ T and NK cells characterised by the expression of the immune checkpoint LAG3 and the presence of the adaptive NK cell subset. An increased frequency of adaptive NK cells and a reduction of NK cells expressing the activating receptors NKp30 and NKp46 correlated with disease severity. Although both activated and exhausted NK cells expressing LAG3 were increased in moderate/severe cases, unsupervised cell clustering analyses revealed a more complex scenario with single NK cells expressing more than one immune checkpoint (PD1, TIM3 and/or LAG3). A general increased level of inflammatory cytokines and chemokines was found in COVID19 patients, some of which like IL18, IL1RA, IL36B and IL31, IL2, IFN alpha and TNF alpha, CXCL10, CCL2 and CCL8 were able to differentiate between COVID19 and NON-COV-RTI and correlated with bad prognosis (IL2, TNF alpha, IL1RA, CCL2, CXCL10 and CXCL9). Notably, we found that soluble NKG2D ligands from the MIC and ULBPs families were increased in COVID19 compared to NON-COV-RTI and correlated with disease severity. Conclusions: Our results provide a detailed comprehensive analysis of the presence of activated and exhausted CD8+T, NK and monocyte cell subsets as well as extracellular inflammatory factors beyond cytokines/chemokines, specifically associated to COVID19. Importantly, multivariate analysis including clinical, demographical and immunological experimental variables have allowed us to reveal specific immune signatures to i) differentiate COVID19 from other infections and ii) predict disease severity and the risk of death.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Integration of In silico and in vitro analysis of gliotoxin production reveals a narrow range of producing fungal species

  • Redrado, S.
  • Esteban, P.
  • Domingo, M. P.
  • López, C.
  • Rezusta, A.
  • Ramirez-Labrada, A.
  • Arias, M.
  • Pardo, J.
  • Galvez, E. M.
Gliotoxin is a fungal secondary metabolite with impact on health and agriculture since it might act as virulence factor and contaminate human and animal food. Homologous gliotoxin (GT) gene clusters are spread across a number of fungal species although if they produce GT or other related epipolythiodioxopiperazines (ETPs) remains obscure. Using bioinformatic tools, we have identified homologous gli gene clusters similar to the A. fumigatus GT gene cluster in several fungal species. In silico study led to in vitro confirmation of GT and Bisdethiobis(methylthio)gliotoxin (bmGT) production in fungal strain cultures by HPLC detection. Despite we selected most similar homologous gli gene cluster in 20 different species, GT and bmGT were only detected in section Fumigati species and in a Trichoderma virens Q strain. Our results suggest that in silico gli homology analyses in different fungal strains to predict GT production might be only informative when accompanied by analysis about mycotoxin production in cell cultures.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Adoptive NK Cell Transfer as a Treatment in Colorectal Cancer Patients: Analyses of Tumour Cell Determinants Correlating With Efficacy In Vitro and In Vivo

  • Lanuza, P. M.
  • Alonso, M. H.
  • Hidalgo, S.
  • Uranga-Murillo, I.
  • García-Mulero, S.
  • Arnau, R.
  • Santos, C.
  • Sanjuan, X.
  • Santiago, L.
  • Comas, L.
  • Redrado, S.
  • Pazo-Cid, R.
  • Agustin-Ferrández, M. J.
  • Jaime-Sánchez, P.
  • Pesini, C.
  • Gálvez, E. M.
  • Ramírez-Labrada, A.
  • Arias, M.
  • Sanz-Pamplona, R.
  • Pardo Jimeno, J.
Background: Colorectal cancer (CRC) is a heterogeneous disease with variable mutational profile and tumour microenvironment composition that influence tumour progression and response to treatment. While chemoresistant and poorly immunogenic CRC remains a challenge, the development of new strategies guided by biomarkers could help stratify and treat patients. Allogeneic NK cell transfer emerges as an alternative against chemoresistant and poorly immunogenic CRC. Methods: NK cell-related immunological markers were analysed by transcriptomics and immunohistochemistry in human CRC samples and correlated with tumour progression and overall survival. The anti-tumour ability of expanded allogeneic NK cells using a protocol combining cytokines and feeder cells was analysed in vitro and in vivo and correlated with CRC mutational status and the expression of ligands for immune checkpoint (IC) receptors regulating NK cell activity. Results: HLA-I downmodulation and NK cell infiltration correlated with better overall survival in patients with a low-stage (II) microsatellite instability-high (MSI-H) CRC, suggesting a role of HLA-I as a prognosis biomarker and a potential benefit of NK cell immunotherapy. Activated allogeneic NK cells were able to eliminate CRC cultures without PD-1 and TIM-3 restriction but were affected by HLA-I expression. In vivo experiments confirmed the efficacy of the therapy against both HLA+ and HLA- CRC cell lines. Concomitant administration of pembrolizumab failed to improve tumour control. Conclusions: Our results reveal an immunological profile of CRC tumours in which immunogenicity (MSI-H) and immune evasion mechanisms (HLA downmodulation) favour NK cell immunosurveillance at early disease stages. Accordingly, we have shown that allogeneic NK cell therapy can target tumours expressing mutations conferring poor prognosis regardless of the expression of T cell-related inhibitory IC ligands. Overall, this study provides a rationale for a new potential basis for CRC stratification and NK cell-based therapy. Copyright © 2022 Lanuza, Alonso, Hidalgo, Uranga-Murillo, García-Mulero, Arnau, Santos, Sanjuan, Santiago, Comas, Redrado, Pazo-Cid, Agustin-Ferrández, Jaime-Sánchez, Pesini, Gálvez, Ramírez-Labrada, Arias, Sanz-Pamplona and Pardo.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

All about (nk cell-mediated) death in two acts and an unexpected encore: initiation, execution and activation of adaptive immunity

  • Ramírez-Labrada, Ariel
  • Pesini, Cecilia
  • Santiago, Llipsy
  • Hidalgo, Sandra
  • Calvo-Pérez, Adanays
  • Oñate, Carmen
  • Andrés Tovar, A.
  • Garzón-Tituaña, Mar
  • Uranga-Murillo, Iratxe
  • Arias, Maykel A.
  • Galvez, Eva M.
  • Pardo, Julián
NK cells are key mediators of immune cell-mediated cytotoxicity toward infected and transformed cells, being one of the main executors of cell death in the immune system. NK cells recognize target cells through an array of inhibitory and activating receptors for endogenous or exogenous pathogen-derived ligands, which together with adhesion molecules form a structure known as immunological synapse that regulates NK cell effector functions. The main and best characterized mechanisms involved in NK cell-mediated cytotoxicity are the granule exocytosis pathway (perforin/granzymes) and the expression of death ligands. These pathways are recognized as activators of different cell death programmes on the target cells leading to their destruction. However, most studies analyzing these pathways have used pure recombinant or native proteins instead of intact NK cells and, thus, extrapolation of the results to NK cell-mediated cell death might be difficult. Specially, since the activation of granule exocytosis and/or death ligands during NK cell-mediated elimination of target cells might be influenced by the stimulus received from target cells and other microenvironment components, which might affect the cell death pathways activated on target cells. Here we will review and discuss the available experimental evidence on how NK cells kill target cells, with a special focus on the different cell death modalities that have been found to be activated during NK cell-mediated cytotoxicity; including apoptosis and more inflammatory pathways like necroptosis and pyroptosis. In light of this new evidence, we will develop the new concept of cell death induced by NK cells as a new regulatory mechanism linking innate immune response with the activation of tumour adaptive T cell responses, which might be the initiating stimulus that trigger the cancer-immunity cycle. The use of the different cell death pathways and the modulation of the tumour cell molecular machinery regulating them might affect not only tumour cell elimination by NK cells but, in addition, the generation of T cell responses against the tumour that would contribute to efficient tumour elimination and generate cancer immune memory preventing potential recurrences.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Silver nanoparticles–polyethyleneimine-based coatings with antiviral activity against SARS-CoV-2: a new method to functionalize filtration media

  • Baselga, M.
  • Uranga-Murillo, I.
  • de Miguel, D.
  • Arias, M.
  • Sebastián, V.
  • Pardo, J.
  • Arruebo, M.
The use of face masks and air purification systems has been key to curbing the transmission of SARS-CoV-2 aerosols in the context of the current COVID-19 pandemic. However, some masks or air conditioning filtration systems are designed to remove large airborne particles or bacteria from the air, being limited their effectiveness against SARS-CoV-2. Continuous research has been aimed at improving the performance of filter materials through nanotechnology. This article presents a new low-cost method based on electrostatic forces and coordination complex formation to generate antiviral coatings on filter materials using silver nanoparticles and polyethyleneimine. Initially, the AgNPs synthesis procedure was optimized until reaching a particle size of 6.2 ± 2.6 nm, promoting a fast ionic silver release due to its reduced size, obtaining a stable colloid over time and having reduced size polydispersity. The stability of the binding of the AgNPs to the fibers was corroborated using polypropylene, polyester-viscose, and polypropylene-glass spunbond mats as substrates, obtaining very low amounts of detached AgNPs in all cases. Under simulated operational conditions, a material loss less than 1% of nanostructured silver was measured. SEM micrographs demonstrated high silver distribution homogeneity on the polymer fibers. The antiviral coatings were tested against SARS-CoV-2, obtaining inactivation yields greater than 99.9%. We believe our results will be beneficial in the fight against the current COVID-19 pandemic and in controlling other infectious airborne pathogens. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

No evidence of SARS-CoV-2 infection in wild mink (Mustela lutreola and neogale vison) from northern Spain during the first two years of pandemic

  • Villanueva Saz, S.
  • Giner, J.
  • Palomar, A. M.
  • Gómez, M. A.
  • Põdra, M.
  • Aranda, M. C.
  • Jiménez, M. A.
  • Lizarraga, P.
  • Hernández, R.
  • Portillo, A.
  • Oteo, J. A.
  • Ruíz-Arrondo, I.
  • Pérez, M. D.
  • Tobajas, A. P.
  • Verde, M.
  • Lacasta, D.
  • Marteles, D.
  • Hurtado-Guerrero, R.
  • Santiago, L.
  • Ruiz, H.
  • Fernández, A.
The impact of the SARS-CoV-2 pandemic on wildlife is largely unevaluated, and extended surveillance of animal species is needed to reach a consensus on the role of animals in the emergence and maintenance of SARS-CoV-2. This infection has been detected in farmed and domestic animals and wild animals, mainly in captivity. The interactions or shared resources with wildlife could represent a potential transmission pathway for the SARS-CoV-2 spill over to other wild species and could lead to health consequences or the establishment of new reservoirs in susceptible hosts. This study evaluated the presence of SARS-CoV-2 in European mink (Mustela lutreola) and American mink (Neogale vison) in Spain by enzyme-linked immunosorbent assay (ELISA) using the receptor binding domain (RBD) of Spike antigen in serum samples and/or by RT-qPCR assays in oropharyngeal and rectal swabs. From January 2020 to February 2022, a total of 162 animals (127 European mink and 35 American mink) with no evidence of SARS-CoV-2 infection were included in the study. Antibodies against the SARS-CoV-2 were not found in the serum samples analysed (n = 126), nor was the virus amplified by RT-qPCR (n = 160 swabs). Our results suggest that the potential role of wild mink and the European mink bred in captivity and released to the wild as dispersers of SARS-CoV-2 is so far low. However, wildlife surveillance for early detection of human and animal risks should be continued. In this sense, epidemiological monitoring measures, including serology and molecular analysis, are necessary.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Hemizygous Granzyme A Mice Expressing the hSOD1G93A Transgene Show Slightly Extended Lifespan

  • Moreno-Martinez, Laura
  • Santiago, Llipsy
  • de la Torre, Miriam
  • Calvo, Ana Cristina
  • Pardo, Julián
  • Osta, Rosario
Granzyme A (gzmA), a serine protease involved in the modulation of the inflammatory immune response, is found at an elevated level in the serum from ALS patients. However, the influence of gzmA on the progression of ALS remains unclear. The aim of our work was to assess whether the absence of gzmA in an ALS murine model could help slow down the progression of the disease. Homozygous and hemizygous gzmA-deficient mice expressing the hSOD1G93A transgene were generated, and survival of these mice was monitored. Subsequently, gene and protein expression of inflammatory and oxidative stress markers was measured in the spinal cord and quadriceps of these mice. We observed the longest lifespan in gzmA+/− mice. GzmA gene and protein expression was downregulated in the spinal cord and serum from gmzA+/− mice, confirming that the increased survival of hemizygous mice is correlated with lower levels of gzmA. In addition, mRNA and protein levels of glutathione reductase (GSR), involved in oxidative stress, were found downregulated in the spinal cord and quadriceps of gmzA+/− mice, together with lower IL-1β and IL-6 mRNA levels in hemyzigous mice. In summary, our findings indicate for the first time that reduced levels, but not the absence, of gzmA could slightly ameliorate the disease progression in this animal model.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

A Subset of PD-1-Expressing CD56bright NK Cells Identifies Patients with Good Response to Immune Checkpoint Inhibitors in Lung Cancer

  • Gascón-Ruiz, Marta
  • Ramírez-Labrada, Ariel
  • Lastra, Rodrigo
  • Martínez-Lostao, Luis
  • Paño-Pardo, J. Ramón
  • Sesma, Andrea
  • Zapata-García, María
  • Moratiel, Alba
  • Quílez, Elisa
  • Torres-Ramón, Irene
  • Yubero, Alfonso
  • Domingo, María Pilar
  • Esteban, Patricia
  • Gálvez, Eva M.
  • Pardo, Julián
  • Isla, Dolores
(1) Despite the effectiveness of immune checkpoint inhibitors (ICIs) in lung cancer, there is a lack of knowledge about predictive biomarkers. The objective of our study is to analyze different subsets of T-lymphocytes and natural killer (NK) cells as predictive biomarkers in a cohort of patients with nonsmall cell lung cancer (NSCLC) treated with ICI. (2) This is an observational, prospective study with 55 NSCLC patients treated with ICI. A total of 43 T and NK cell subsets are analyzed in peripheral blood, including the main markers of exhaustion, differentiation, memory, activation, and inhibition. (3) Regarding the descriptive data, Granzyme B+CD4+ Treg lymphocytes stand out (median 17.4%), and within the NK populations, most patients presented cytotoxic NK cells (CD56+CD3−CD16+GranzymeB+; median 94.8%), and about half of them have highly differentiated adaptive-like NK cells (CD56+CD3−CD16+CD57+ (mean 59.8%). A statistically significant difference was observed between the expression of PD1 within the CD56bright NK cell subpopulation (CD56+CD3−CD16−PD-1+) (p = 0.047) and a better OS. (4) Circulating immune cell subpopulations are promising prognostic biomarkers for ICI. Pending on validation with a larger sample, here we provide an analysis of the major circulating T and NK cell subsets involved in cancer immunity, with promising results despite a small sample size.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Serum lipid mediator profiles in COVID-19 patients and lung disease severity: a pilot study

  • Irún, Pilar
  • Gracia, Rafael
  • Piazuelo, Elena
  • Pardo, Julián
  • Morte, Elena
  • Paño, José Ramon
  • Boza, Julio
  • Carrera-Lasfuentes, Patricia
  • Higuera, Gustavo A.
  • Lanas, Ángel
Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is highly heterogeneous, ranging from asymptomatic to severe and fatal cases. COVID-19 has been characterized by an increase of serum pro-inflammatory cytokine levels which seems to be associated with fatal cases. By contrast, the role of pro-resolving lipid mediators (SPMs), involved in the attenuation of inflammatory responses, has been scarcely investigated, so further studies are needed to understand SPMs metabolism in COVID-19 and other infectious diseases. Our aim was to analyse the lipid mediator metabolome, quantifying pro- and anti-inflammatory serum bioactive lipids by LC–MS/MS in 7 non-infected subjects and 24 COVID-19 patients divided into mild, moderate, and severe groups according to the pulmonary involvement, to better understand the disease outcome and the severity of the pulmonary manifestations. Statistical analysis was performed with the R programming language (R Foundation for Statistical Computing, Vienna, Austria). All COVID-19 patients had increased levels of Prostaglandin E2. Severe patients showed a significant increase versus controls, mild- and moderate-affected patients, expressed as median (interquartile range), in resolvin E1 [112.6 (502.7) vs 0.0 (0.0) pg/ml in the other groups], as well as in maresin 2 [14.5 (7.0) vs 8.1 (4.2), 5.5 (4.3), and 3.0 (4.0) pg/ml, respectively]. Moreover, 14-hydroxy docosahexaenoic acid (14-HDHA) levels were also increased in severe vs control and mild-affected patients [24.7 (38.2) vs 2.4 (2.2) and 3.7 (6.4) ng/mL, respectively]. Resolvin D5 was also significantly elevated in both moderate [15.0 (22.4) pg/ml] and severe patients [24.0 (24.1) pg/ml] versus controls [0.0 (0.0) pg/ml]. These results were confirmed by sparse partial least squares discriminant analysis which highlighted the contribution of these mediators to the separation between each of the groups. In conclusion, the potent inflammatory response to SARS-CoV-2 infection involves not only pro- but also anti-inflammatory lipid mediators that can be quantified in easily accessible serum samples, suggesting the need to perform future research on their generation pathways that will help us to discover new therapeutic targets.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Granzyme-A deficiency attenuates experimental osteoarthritis in mice, but perforin deficiency does not

  • Calvo, Jorge
  • Santiago, Llipsy
  • Arias, Maykel
  • Pardo, Julián
  • Albareda, Jorge
  • Martínez-Lostao, Luis
  • García-Alvarez, Felícito
Objectives: This study aims to assess the development of osteoarthritis (OA) in granzyme A- (gzmA) and B- (gzmB) and perforin- (perf) knockout mice. Materials and methods: A total of 75 male and female C57BL/6 (eight to nine-week-old) mice were allocated to: gzmA-deficient (gzmA-/-) (11 females, 8 males), gzmB-deficient (gzmB-/-) (9 females, 8 males), perf-deficient (perf-/-) (10 females, 9 males), and control group (10 females, 10 males). Osteoarthritis was induced in the right knee by instability of the meniscus medial ligament. Sham surgery was practiced in the left knee. Knee samples obtained eight weeks after surgery were stained (Safranin-O) and blindly scored in lateral and medial femur and tibia using the Osteoarthritis Research Society International scale (OARSI) (from Grade 0, cartilage intact to 6, deformation), (five stages from 0, no OA to 4, >50% surface involvement); OARSI score (grade x stage); and a semi-quantitative scale from Grade 0 (normal) to 6 (cartilage erosion >80%). Results: Significantly higher values in all scales in the right knees compared to the left knees in male and female mice were observed (p<0.05). Males of all strains showed in the right knee higher values than females on all scales. Deficiency of perforin did not modify OA severity in any sex. The gzmA-/- females presented less degenerative changes than the other groups. Conclusion: Our study results show that sex plays an important role in the development of experimental OA in mice. Deficiency of gzmA can protect from the development of OA in female mice.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Fluorogenic Granzyme A Substrates Enable Real-Time Imaging of Adaptive Immune Cell Activity

  • Cheng, Zhiming
  • Thompson, Emily J
  • Mendive-Tapia, Lorena
  • Scott, Jamie I
  • Benson, Sam
  • Kitamura, Takanori
  • Senan-Salinas, Ana
  • Samarakoon, Youhani
  • Roberts, Edward W
  • Arias, Maykel A
  • Pardo, Julian
  • Galvez, Eva M
  • Vendrell, Marc
Cytotoxic immune cells, including T lymphocytes (CTLs) and natural killer (NK) cells, are essential components of the host response against tumors. CTLs and NK cells secrete granzyme A (GzmA) upon recognition of cancer cells; however, there are very few tools that can detect physiological levels of active GzmA with high spatiotemporal resolution. Herein, we report the rational design of the near‐infrared fluorogenic substrates for human GzmA and mouse GzmA. These activity‐based probes display very high catalytic efficiency and selectivity over other granzymes, as shown in tissue lysates from wild‐type and GzmA knock‐out mice. Furthermore, we demonstrate that the probes can image how adaptive immune cells respond to antigen‐driven recognition of cancer cells in real time.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Unravelling the cellular response to the SARS-COV-2 vaccine in inflammatory bowel disease patients on biologic drugs

  • Martínez-Domínguez, Samuel J.
  • García-Mateo, Sandra
  • Sainz-Arnal, Pilar
  • Martínez-García, Javier
  • Gallego-Llera, Beatriz
  • Lozano-Limones, María Jesús
  • Hidalgo, Sandra
  • Gargallo-Puyuelo, Carla J.
  • Latre-Santos, Marta
  • Nocito-Colon, Maria Mercedes Lourdes
  • Martínez-Lostao, Luis
  • Refaie, Engy
  • Arroyo-Villarino, Maria Teresa
  • del Rio-Nechaevsky, Marcela
  • Ramirez-Labrada, Ariel
  • Pardo, Julián
  • Gomollón, Fernando
  • Baptista, Pedro M.
Suboptimal vaccine response is a significant concern in patients with Inflammatory Bowel Disease (IBD) receiving biologic drugs. This single-center observational study involved 754 patients with IBD. In Phase I (October 2020-April 2021), 754 IBD participants who had not previously received the SARS-CoV-2 vaccine, underwent blood extraction to assess the seroprevalence of SARS-CoV-2 infection and IBD-related factors. Phase II (May 2021-October 2021) included a subgroup of 52 IBD participants with confirmed previous SARS-CoV-2 infection, who were studied for humoral and cellular response to the SARS-CoV-2 vaccine. In Phase I, treatment with anti-TNF was associated with lower rates of seroconversion (aOR 0.25 95% CI [0.10–0.61]). In Phase II, a significant increase in post-vaccination IgG levels was observed regardless of biologic treatment. However, patients treated with anti-TNF exhibited significantly lower IgG levels compared to those without IBD therapy (5.32 ± 2.47 vs. 7.99 ± 2.59 U/ml, p = 0.042). Following vaccination, a lymphocyte, monocyte, and NK cell activation pattern was observed, with no significant differences between patients receiving biologic drugs and those without IBD treatment. Despite lower seroprevalence and humoral response to the SARS-CoV-2 vaccine in patients treated with anti-TNF, the cellular response to the vaccine did not differ significantly from that patients without IBD therapy.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

CAR immunotherapy for the treatment of infectious diseases: a systematic review

  • Morte-Romea, Elena
  • Pesini, Cecilia
  • Pellejero-Sagastizábal, Galadriel
  • Letona-Giménez, Santiago
  • Martínez-Lostao, Luis
  • Loscos Aranda, Silvia
  • Toyas, Carla
  • Redrado, Sergio
  • Dolader-Ballesteros, Elena
  • Arias, Maykel
  • Galvez, Eva M.
  • Sanz-Pamplona, Rebeca
  • Pardo, Julián
  • Paño-Pardo, Jose Ramón
  • Ramírez-Labrada, Ariel
Immunotherapy treatments aim to modulate the host’s immune response to either mitigate it in inflammatory/autoimmune disease or enhance it against infection or cancer. Among different immunotherapies reaching clinical application during the last years, chimeric antigen receptor (CAR) immunotherapy has emerged as an effective treatment for cancer where different CAR T cells have already been approved. Yet their use against infectious diseases is an area still relatively poorly explored, albeit with tremendous potential for research and clinical application. Infectious diseases represent a global health challenge, with the escalating threat of antimicrobial resistance underscoring the need for alternative therapeutic approaches. This review aims to systematically evaluate the current applications of CAR immunotherapy in infectious diseases and discuss its potential for future applications. Notably, CAR cell therapies, initially developed for cancer treatment, are gaining recognition as potential remedies for infectious diseases. The review sheds light on significant progress in CAR T cell therapy directed at viral and opportunistic fungal infections.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Multiparametric in vitro and in vivo analysis of the safety profile of self-assembling peptides

  • Ramirez-Labrada, Ariel
  • Santiago, Llipsy
  • Pesini, Cecilia
  • Arrieta, Marta
  • Arias, Maykel
  • Calvo Pérez, Adanays
  • Ciulla, Maria Gessica
  • Forouharshad, Mahdi
  • Pardo, Julian
  • Gálvez, Eva M.
  • Gelain, Fabrizio
Self-assembling peptides (SAPs) have gained significant attention in biomedicine because of their unique properties and ability to undergo molecular self-assembly driven by non-covalent interactions. By manipulating their composition and structure, SAPs can form well-ordered nanostructures with enhanced selectivity, stability and biocompatibility. SAPs offer advantages such as high chemical and biological diversity and the potential for functionalization. However, studies concerning its potentially toxic effects are very scarce, a limitation that compromises its potential translation to humans. This study investigates the potentially toxic effects of six different SAP formulations composed of natural amino acids designed for nervous tissue engineering and amenable to ready cross-linking boosting their biomechanical properties. All methods were performed in accordance with the relevant guidelines and regulations. A wound-healing assay was performed to evaluate how SAPs modify cell migration. The results in vitro demonstrated that SAPs did not induce genotoxicity neither skin sensitization. In vivo, SAPs were well-tolerated without any signs of acute systemic toxicity. Interestingly, SAPs were found to promote the migration of endothelial, macrophage, fibroblast, and neuronal-like cells in vitro, supporting a high potential for tissue regeneration. These findings contribute to the development and translation of SAP-based biomaterials for biomedical applications.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Biomarkers of immunotherapy response in patients with non-small-cell lung cancer: microbiota composition, short-chain fatty acids, and intestinal permeability

  • Moratiel-Pellitero, Alba
  • Zapata-García, María
  • Gascón Ruiz, Marta
  • Sesma, Andrea
  • Quílez, Elisa
  • Ramírez-Labrada, Ariel
  • Martínez-Lostao, Luis
  • Domingo, María Pilar
  • Esteban, Patricia
  • Yubero, Alfonso
  • Barbero-Herranz, Raquel
  • Moreno-Blanco, Ana
  • Paño, José Ramón
  • Lastra, Rodrigo
  • Pardo, Julián
  • Isla, Dolores
  • Campo, Rosa del
  • Gálvez, Eva
Immune checkpoint inhibitors have been proposed as the standard treatment for different stages of non-small-cell lung cancer in multiple indications. Not all patients benefit from these treatments, however, and certain patients develop immune-related adverse events. Although the search for predictors of response to these drugs is a major field of research, these issues have yet to be resolved. It has been postulated that microbiota could play a relevant role in conditioning the response to cancer treatments; however, the human factor of intestinal permeability also needs to be considered as it is closely related to the regulation of host–microbiota interaction. In this article, we analyzed the possible relationship between the response to immune checkpoint inhibitors and the onset of immune-related adverse events, gut microbiota status, and intestinal membrane permeability. In a pioneering step, we also measured short-chain fatty acid content in feces. Although the correlation analyses failed to identify predictive biomarkers, even when all variables were integrated, our patients’ microbial gut ecosystems were rich and diverse, and the intestinal barrier’s integrity was preserved. These results add new knowledge on the composition of microbiota and its correlation with barrier permeability and short-chain fatty acids and suggest that more studies are required before these potential biomarkers can be incorporated into the clinical management of patients via immune checkpoint inhibitor treatment.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Identification of FasL as a crucial host factor driving COVID-19 pathology and lethality

  • Albert, Marie-Christine
  • Uranga-Murillo, Iratxe
  • Arias, Maykel
  • De Miguel, Diego
  • Peña, Natacha
  • Montinaro, Antonella
  • Varanda, Ana Beatriz
  • Theobald, Sebastian J.
  • Areso, Itziar
  • Saggau, Julia
  • Koch, Manuel
  • Liccardi, Gianmaria
  • Peltzer, Nieves
  • Rybniker, Jan
  • Hurtado-Guerrero, Ramón
  • Merino, Pedro
  • Monzón, Marta
  • Badiola, Juan J.
  • Reindl-Schwaighofer, Roman
  • Sanz-Pamplona, Rebeca
  • Cebollada-Solanas, Alberto
  • Megyesfalvi, Zsolt
  • Dome, Balazs
  • Secrier, Maria
  • Hartmann, Boris
  • Bergmann, Michael
  • Pardo, Julián
  • Walczak, Henning
The dysregulated immune response and inflammation resulting in severe COVID-19 are still incompletely understood. Having recently determined that aberrant death-ligand-induced cell death can cause lethal inflammation, we hypothesized that this process might also cause or contribute to inflammatory disease and lung failure following SARS-CoV-2 infection. To test this hypothesis, we developed a novel mouse-adapted SARS-CoV-2 model (MA20) that recapitulates key pathological features of COVID-19. Concomitantly with occurrence of cell death and inflammation, FasL expression was significantly increased on inflammatory monocytic macrophages and NK cells in the lungs of MA20-infected mice. Importantly, therapeutic FasL inhibition markedly increased survival of both, young and old MA20-infected mice coincident with substantially reduced cell death and inflammation in their lungs. Intriguingly, FasL was also increased in the bronchoalveolar lavage fluid of critically-ill COVID-19 patients. Together, these results identify FasL as a crucial host factor driving the immuno-pathology that underlies COVID-19 severity and lethality, and imply that patients with severe COVID-19 may significantly benefit from therapeutic inhibition of FasL.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Selective Detection of Active Extracellular Granzyme A by Using a Novel Fluorescent Immunoprobe with Application to Inflammatory Diseases

  • Senan-Salinas, Ana
  • Comas, Laura
  • Esteban, Patricia
  • Garzón-Tituaña, Marcela
  • Cheng, Zhiming
  • Santiago, Llipsy
  • Domingo, Maria Pilar
  • Ramírez-Labrada, Ariel
  • Paño-Pardo, José Ramón
  • Vendrell, Marc
  • Pardo, Julián
  • Arias, Maykel A.
  • Galvez, Eva M.
Granzymes (Gzms), a family of serine proteases, expressed by immune and nonimmune cells, present perforin-dependent and independent intracellular and extracellular functions. When released in the extracellular space, GzmA, with trypsin-like activity, is involved in the pathophysiology of different inflammatory diseases. However, there are no validated specific systems to detect active forms of extracellular GzmA, making it difficult to assess its biological relevance and potential use as a biomarker. Here, we have developed fluorescence-energy resonance-transfer (FRET)-based peptide probes (FAM-peptide-DABCYL) to specifically detect GzmA activity in tissue samples and biological fluids in both mouse and human samples during inflammatory diseases. An initial probe was developed and incubated with GzmA and different proteases like GzmB and others with similar cleavage specificity as GzmA like GzmK, thrombin, trypsin, kallikrein, or plasmin. After measuring fluorescence, the probe showed very good specificity and sensitivity for human and mouse GzmA when compared to GzmB, its closest homologue GzmK, and with thrombin. The specificity of this probe was further refined by incubating the samples in a coated plate with a GzmA-specific antibody before adding the probe. The results show a high specific detection of soluble GzmA even when compared with other soluble proteases with very similar cleavage specificity like thrombin, GzmK, trypsin, kallikrein, or plasmin, which shows nearly no fluorescence signal. The high specific detection of GzmA was validated, showing that using pure proteins and serum and tissue samples from GzmA-deficient mice presented a significant reduction in the signal compared with WT mice. The utility of this system in humans was confirmed, showing that GzmA activity was significantly higher in serum samples from septic patients in comparison with healthy donors. Our results present a new immunoprobe with utility to detect extracellular GzmA activity in different biological fluids, confirming the presence of active forms of the soluble protease in vivo during inflammatory and infectious diseases.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

The importance of murine phospho-MLKL-S345 in situ detection for necroptosis assessment in vivo

  • Kelepouras, Konstantinos
  • Saggau, Julia
  • Varanda, Ana Beatriz
  • Zrilic, Matea
  • Kiefer, Christine
  • Rakhsh-Khorshid, Hassan
  • Lisewski, Ina
  • Uranga-Murillo, Iratxe
  • Arias, Maykel
  • Pardo, Julian
  • Tonnus, Wulf
  • Linkermann, Andreas
  • Annibaldi, Alessandro
  • Walczak, Henning
  • Liccardi, Gianmaria
Necroptosis is a caspase-independent modality of cell death implicated in many inflammatory pathologies. The execution of this pathway requires the formation of a cytosolic platform that comprises RIPK1 and RIPK3 which, in turn, mediates the phosphorylation of the pseudokinase MLKL (S345 in mouse). The activation of this executioner is followed by its oligomerisation and accumulation at the plasma-membrane where it leads to cell death via plasma-membrane destabilisation and consequent permeabilisation. While the biochemical and cellular characterisation of these events have been amply investigated, the study of necroptosis involvement in vivo in animal models is currently limited to the use of Mlkl−/− or Ripk3−/− mice. Yet, even in many of the models in which the involvement of necroptosis in disease aetiology has been genetically demonstrated, the fundamental in vivo characterisation regarding the question as to which tissue(s) and specific cell type(s) therein is/are affected by the pathogenic necroptotic death are missing. Here, we describe and validate an immunohistochemistry and immunofluorescence-based method to reliably detect the phosphorylation of mouse MLKL at serine 345 (pMLKL-S345). We first validate the method using tissues derived from mice in which Caspase-8 (Casp8) or FADD are specifically deleted from keratinocytes, or intestinal epithelial cells, respectively. We next demonstrate the presence of necroptotic activation in the lungs of SARS-CoV-infected mice and in the skin and spleen of mice bearing a Sharpin inactivating mutation. Finally, we exclude necroptosis occurrence in the intestines of mice subjected to TNF-induced septic shock. Importantly, by directly comparing the staining of pMLKL-345 with that of cleaved Caspase-3 staining in some of these models, we identify spatio-temporal and functional differences between necroptosis and apoptosis supporting a role of RIPK3 in inflammation independently of MLKL versus the role of RIPK3 in activation of necroptosis.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

An agent-based method to estimate 3D cell migration trajectories from 2D measurements: Quantifying and comparing T vs CAR-T 3D cell migration

  • Camacho-Gómez, Daniel
  • Movilla, Nieves
  • Borau, Carlos
  • Martín, Alejandro
  • Oñate Salafranca, Carmen
  • Pardo, Julián
  • Gómez-Benito, María José
  • García-Aznar, José Manuel
Background and objective: Immune cell migration is one of the key features that enable immune cells to find invading pathogens, control tissue damage, and eliminate primary developing tumors. Chimeric antigen receptor (CAR) T-cell therapy is a novel strategy in the battle against various cancers. It has been successful in treating hematological tumors, yet it still faces many challenges in the case of solid tumors. In this work, we evaluate the three-dimensional (3D) migration capacity of T and CAR-T cells within dense collagen-based hydrogels. Quantifying three-dimensional (3D) cell migration requires microscopy techniques that may not be readily accessible. Thus, we introduce a straightforward mathematical model designed to infer 3D trajectories of cells from two-dimensional (2D) cell trajectories. Methods: We develop a 3D agent-based model (ABM) that simulates the temporal changes in the direction of migration with an inverse transform sampling method. Then, we propose an optimization procedure to accurately orient cell migration over time to reproduce cell migration from 2D experimental cell trajectories. With this model, we simulate cell migration assays of T and CAR-T cells in microfluidic devices conducted under hydrogels with different concentrations of type I collagen and validate our 3D cell migration predictions with light-sheet microscopy. Results: Our findings indicate that CAR-T cell migration is more sensitive to collagen concentration increases than T cells, resulting in a more pronounced reduction in their invasiveness. Moreover, our computational model reveals significant differences in 3D movement patterns between T and CAR-T cells. T cells exhibit migratory behavior in 3D whereas that CAR-T cells predominantly move within the plane, with limited movement in the direction. However, upon the introduction of a CXCL12 chemical gradient, CAR-T cells present migration patterns that closely resemble those of T cells. Conclusions: This framework demonstrates that 2D projections of 3D trajectories may not accurately represent real migration patterns. Moreover, it offers a tool to estimate 3D migration patterns from 2D experimental data, which can be easily obtained with automatic quantification algorithms. This approach helps reduce the need for sophisticated and expensive microscopy equipment required in laboratories, as well as the computational burden involved in producing and analyzing 3D experimental data.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Reseña (Review)

In-depth analysis of the interplay between oncogenic mutations and NK cell-mediated cancer surveillance in solid tumors

  • Pesini, Cecilia
  • Artal, Laura
  • Paúl Bernal, Jorge
  • Sánchez Martinez, Diego
  • Pardo, Julián
  • Ramírez-Labrada, Ariel
Natural killer (NK) cells play a crucial role in antitumoral and antiviral responses. Yet, cancer cells can alter themselves or the microenvironment through the secretion of cytokines or other factors, hindering NK cell activation and promoting a less cytotoxic phenotype. These resistance mechanisms, often referred to as the “hallmarks of cancer” are significantly influenced by the activation of oncogenes, impacting most, if not all, of the described hallmarks. Along with oncogenes, other types of genes, the tumor suppressor genes are frequently mutated or modified during cancer. Traditionally, these genes have been associated with uncontrollable tumor growth and apoptosis resistance. Recent evidence suggests oncogenic mutations extend beyond modulating cell death/proliferation programs, influencing cancer immunosurveillance. While T cells have been more studied, the results obtained highlight NK cells as emerging key protagonists for enhancing tumor cell elimination by modulating oncogenic activity. A few recent studies highlight the crucial role of oncogenic mutations in NK cell-mediated cancer recognition, impacting angiogenesis, stress ligands, and signaling balance within the tumor microenvironment. This review will critically examine recent discoveries correlating oncogenic mutations to NK cell-mediated cancer immunosurveillance, a relatively underexplored area, particularly in the era dominated by immune checkpoint inhibitors and CAR-T cells. Building on these insights, we will explore opportunities to improve NK cell-based immunotherapies, which are increasingly recognized as promising alternatives for treating low-antigenic tumors, offering significant advantages in terms of safety and manufacturing suitability.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Distinct cell death pathways induced by granzymes collectively protect against intestinal Salmonella infection

  • Chawla, Amanpreet Singh
  • Vandereyken, Maud
  • Arias, Maykel
  • Santiago, Llipsy
  • Dikovskaya, Dina
  • Nguyen, Chi
  • Skariah, Neema
  • Wenner, Nicolas
  • Golovchenko, Natasha B.
  • Thomson, Sarah J.
  • Ondari, Edna
  • Garzón-Tituaña, Marcela
  • Anderson, Christopher J.
  • Bergkessel, Megan
  • C. D. Hinton, Jay
  • Edelblum, Karen L.
  • Pardo, Julian
  • Swamy, Mahima
Intestinal intraepithelial T lymphocytes (IEL) constitutively express high amounts of the cytotoxic proteases Granzymes (Gzm) A and B and are therefore thought to protect the intestinal epithelium against infection by killing infected epithelial cells. However, the role of IEL granzymes in a protective immune response has yet to be demonstrated. We show that GzmA and GzmB are required to protect mice against oral, but not intravenous, infection with Salmonella enterica serovar Typhimurium, consistent with an intestine-specific role. IEL-intrinsic granzymes mediate the protective effects by controlling intracellular bacterial growth and aiding in cell-intrinsic pyroptotic cell death of epithelial cells. Surprisingly, we found that both granzymes play non-redundant roles. GzmB-/- mice carried significantly lower burdens of Salmonella, as predominant GzmA-mediated cell death effectively reduced bacterial translocation across the intestinal barrier. Conversely, in GzmA-/- mice, GzmB-driven apoptosis favored luminal Salmonella growth by providing nutrients, while still reducing translocation across the epithelial barrier. Together, the concerted actions of both GzmA and GzmB balance cell death mechanisms at the intestinal epithelium to provide optimal control that Salmonella cannot subvert.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Peripheral Blood TCRß Repertoire, IL15, IL2 and Soluble Ligands for NKG2D Activating Receptor Predict Efficacy of Immune Checkpoint Inhibitors in Lung Cancer

  • Sesma, Andrea
  • Pardo, Julian
  • Isla, Dolores
  • M. Gálvez, Eva
  • Gascón-Ruiz, Marta
  • Martínez-Lostao, Luis
  • Moratiel, Alba
  • Paño-Pardo, J. Ramón
  • Quílez, Elisa
  • Torres-Ramón, Irene
  • Yubero, Alfonso
  • Zapata-García, María
  • Domingo, María Pilar
  • Esteban, Patricia
  • Sanz Pamplona, Rebeca
  • Lastra, Rodrigo
  • Ramírez-Labrada, Ariel
The development of immune checkpoint inhibitors (ICIs) has changed the therapeutic paradigm of lung cancer (LC), becoming the standard of treatment for previously untreated advanced non-small cell lung cancer (NSCLC) without actionable mutations. It has allowed the achievement of durable responses and resulted in significant survival benefits. However, not all patients respond; hence, molecular biomarkers are needed to help us predict which patients will respond. With this objective, a prospective observational study was designed, including a cohort of 55 patients with NSCLC who received ICIs. We studied whether biomarkers such as TCRβ and specific cytokines involved in the regulation of T cell activity were related to the immunotherapy response. In the survival analysis, it was found that patients with higher TCRβ clonality, lower TCRβ evenness, higher TCRβ Shannon diversity and lower TCRβ convergence had higher overall survival (OS) and progression-free survival (PFS). However, no statistically significant association was observed. Regarding cytokines, those patients with higher levels of IL-2 and IL-15 presented statistically significantly shorter OS and PFS, respectively. In fact, in the multivariable analysis, the high IL-15 level increased the risk of death by three times. Although the sample size was small and more studies are needed to confirm our results, our study reveals promising markers of responses to ICIs.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Loop engineering of enzymes to control their immobilization and ultimately fabricate more efficient heterogeneous biocatalysts

  • Zeballos, Nicoll
  • Ginés-Alcober, Irene
  • Macías-León, Javier
  • Andrés-Sanz, Daniel
  • González-Ramírez, Andrés Manuel
  • Sánchez-Costa, Mercedes
  • Merino, Pedro
  • Hurtado-Guerrero, Ramón
  • López-Gallego, Fernando
Enzyme immobilization is indispensable for enhancing enzyme performance in various industrial applications. Typically, enzymes require specific spatial arrangements for optimal functionality, underscoring the importance of correct orientation. Despite well‐known N‐ or C‐terminus tailoring techniques, alternatives for achieving orientation control are limited. Here, we propose a novel approach that tailors the enzyme surface with engineered His‐rich loops. To that aim, we first solve the X‐ray crystal structure of a hexameric alcohol dehydrogenase from Thermus thermophilus HB27 (TtHBDH) (PDB: 9FBD). Guided by this 3D structure, we engineer the enzyme surface with a new loop enriched with six His residues to control enzyme orientation. Molecular dynamics simulations reveal that the engineered loop's imidazole rings have greater solvent accessibility than those in native His residues, allowing for more efficient enzyme immobilization on certain metal chelate‐functionalized carriers. Using carriers functionalized with iron (III)‐catechol, the apparent Vmax of the immobilized loop variant doubles the immobilized His‐tagged one, and vice versa when both variants are immobilized on carriers functionalized with copper (II)‐imidodiacetic acid. His‐tagged and loop‐engineered TtHBDH show high operational stability reaching 100% bioconversion after 10 reaction cycles, yet the loop variant is faster than the His‐tagged one.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants

  • Conde E.
  • Vercher E.
  • Soria-Castellano M.
  • Suarez-Olmos J.
  • Mancheno U.
  • Elizalde E.
  • Rodriguez M.L.
  • Glez-Vaz J.
  • Casares N.
  • Rodriguez-Garcia E.
  • Hommel M.
  • Gonzalez-Aseguinolaza G.
  • Uranga-Murillo I.
  • Pardo J.
  • Alkorta G.
  • Melero I.
  • Lasarte J.
  • Hervas-Stubbs S.
Background Target antigen (Ag) loss has emerged as a major cause of relapse after chimeric antigen receptor T (CART)-cell therapy. We reasoned that the combination of CART cells, with the consequent tumor debulking and release of Ags, together with an immunomodulatory agent, such as the stimulator of interferon gene ligand (STING-L) 2'3'-cyclic GMP-AMP (2'3'-cGAMP), may facilitate the activation of an endogenous response to secondary tumor Ags able to counteract this tumor escape mechanism. Methods Mice bearing B16-derived tumors expressing prostate-specific membrane Ag or gp75 were treated systemically with cognate CART cells followed by intratumoral injections of 2'3'-cGAMP. We studied the target Ag inmunoediting by CART cells and the effect of the CART/STING-L combination on the control of STING-L-treated and STING-L-non-treated tumors and on the endogenous antitumor T-cell response. The role of Batf3-dependent dendritic cells (DCs), stimulator of interferon gene (STING) signaling and perforin (Perf)-mediated killing in the efficacy of the combination were analyzed. Results Using an immune-competent solid tumor model, we showed that CART cells led to the emergence of tumor cells that lose the target Ag, recreating the cancer immunoediting effect of CART-cell therapy. In this setting, the CART/STING-L combination, but not the monotherapy with CART cells or STING-L, restrained tumor progression and enhanced overall survival, showing abscopal effects on distal STING-L-non-treated tumors. Interestingly, a secondary immune response against non-chimeric antigen receptor-targeted Ags (epitope spreading), as determined by major histocompatibility complex-I-tetramer staining, was fostered and its intensity correlated with the efficacy of the combination. This was consistent with the oligoclonal expansion of host T cells, as revealed by in-depth T-cell receptor repertoire analysis. Moreover, only in the combination group did the activation of endogenous T cells translate into a systemic antitumor response. Importantly, the epitope spreading and the antitumor effects of the combination were fully dependent on host STING signaling and Batf3-dependent DCs, and were partially dependent on Perf release by CART cells. Interestingly, the efficacy of the CART/STING-L treatment also depended on STING signaling in CART cells. Conclusions Our data show that 2'3'-cGAMP is a suitable adjuvant to combine with CART-cell therapy, allowing the induction of an endogenous T-cell response that prevents the outgrowth of Ag-loss tumor variants.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Biological relevance of Granzymes A and K during E. coli sepsis

  • Uranga-Murillo I.
  • Tapia E.
  • Garzón-Tituaña M.
  • Ramirez-Labrada A.
  • Santiago L.
  • Pesini C.
  • Esteban P.
  • Roig F.J.
  • Galvez E.M.
  • Bird P.I.
  • Pardo Jimeno, J.
  • Arias M.
Aims: Recent in vitro findings suggest that the serine protease Granzyme K (GzmK) may act as a proinflammatory mediator. However, its role in sepsis is unknown. Here we aim to understand the role of GzmK in a mouse model of bacterial sepsis and compare it to the biological relevance of Granzyme A (GzmA). Methods: Sepsis was induced in WT, GzmA-/- and GzmK-/- mice by an intraperitoneal injection of 2x108 CFU from E. coli. Mouse survival was monitored during 5 days. Levels of IL-1a, IL-1ß, TNFa and IL-6 in plasma were measured and bacterial load in blood, liver and spleen was analyzed. Finally, profile of cellular expression of GzmA and GzmK was analyzed by FACS. Results: GzmA and GzmK are not involved in the control of bacterial infection. However, GzmA and GzmK deficient mice showed a lower sepsis score in comparison with WT mice, although only GzmA deficient mice exhibited increased survival. GzmA deficient mice also showed reduced expression of some proinflammatory cytokines like IL1-a, IL-ß and IL-6. A similar result was found when extracellular GzmA was therapeutically inhibited in WT mice using serpinb6b, which improved survival and reduced IL-6 expression. Mechanistically, active extracellular GzmA induces the production of IL-6 in macrophages by a mechanism dependent on TLR4 and MyD88. Conclusions: These results suggest that although both proteases contribute to the clinical signs of E. coli-induced sepsis, inhibition of GzmA is sufficient to reduce inflammation and improve survival irrespectively of the presence of other inflammatory granzymes, like GzmK.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Inflammatory cell death induced by cytotoxic lymphocytes: a dangerous but necessary liaison

  • de Miguel D.
  • Ramirez-Labrada A.
  • Uranga I.
  • Hidalgo S.
  • Santiago L.
  • Galvez E.M.
  • Arias M.
  • Pardo J.
Cytotoxic lymphocytes (CLs), and more specifically Tc and NK cells, are the main executors of cell death in the immune system, playing a key role during both immunosurveillance and immunotherapy. These cells induce regulated cell death (RCD) by different mechanisms, being granular exocytosis and expression of death ligands the most prominent and best characterized ones. Apoptosis, a traditionally considered low-inflammatory type of cell death, has been accepted for years as the paradigm of RCD induced by CLs. However, several recent studies have demonstrated that NK cells and Tc cells can also induce more inflammatory forms of cell death, namely, necroptosis, pyroptosis, and ferroptosis. Activation of these highly inflammatory types of cell death appears to critically contribute to the activation of a successful antitumour immune response. Additionally, the role of specific cell death pathways in immunogenic cell death is still under intense debate, especially considering the interconnections with other inflammatory forms of cell death. These evidences, together with the advent of new cancer immunotherapies, highlight the necessity to deepen our understanding of the link between the cell death triggered by CLs and inflammation. This knowledge will be instrumental to maximize the antitumour potential of immunotherapies, minimizing deleterious effects associated with these treatments. In this review, we will briefly summarize the main features of apoptosis, necroptosis, pyroptosis and ferroptosis, to subsequently discuss the most recent evidences about the role of these RCD pathways during the elimination of cancer cells mediated by CLs and its modulation to increase the efficacy of cancer immunotherapy.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFß and activin A suppression

  • Rea, Anna
  • Santana-Hernández, Sara
  • Villanueva, Javier
  • Sanvicente-García, Marta
  • Cabo, Mariona
  • Suárez-Olmos, Jesús
  • Quimis, Fabricio
  • Qin, Mengjuan
  • Llorens, Eduard
  • Blasco-Benito, Sandra
  • Torralba-Raga, Lamberto
  • Pérez, Lorena
  • Bhattarai, Bishan
  • Alari-Pahissa, Elisenda
  • Georgoudaki, Anna-Maria
  • Balaguer, Francesc
  • Juan, Manel
  • Pardo, Julián
  • Celià-Terrassa, Toni
  • Rovira, Ana
  • Möker, Nina
  • Zhang, Congcong
  • Colonna, Marco
  • Spanholtz, Jan
  • Malmberg, Karl-Johan
  • Montagut, Clara
  • Albanell, Joan
  • Güell, Marc
  • López-Botet
  • Muntasell, Aura
Transforming growth factor beta (TGFβ) and activin A suppress natural killer (NK) cell function and proliferation, limiting the efficacy of adoptive NK cell therapies. Inspired by the partial resistance to TGFβ of NK cells with SMAD4 haploinsufficiency, we used CRISPR–Cas9 for knockout of SMAD4 in human NK cells. Here we show that SMAD4KO NK cells were resistant to TGFβ and activin A inhibition, retaining their cytotoxicity, cytokine secretion and interleukin-2/interleukin-15-driven proliferation. They showed enhanced tumor penetration and tumor growth control, both as monotherapy and in combination with tumor-targeted therapeutic antibodies. Notably, SMAD4KO NK cells outperformed control NK cells treated with a TGFβ inhibitor, underscoring the benefit of maintaining SMAD4-independent TGFβ signaling. SMAD4KO conferred TGFβ resistance across diverse NK cell platforms, including CD19-CAR NK cells, stem cell-derived NK cells and ADAPT-NK cells. These findings position SMAD4 knockout as a versatile and compelling strategy to enhance NK cell antitumor activity, providing a new avenue for improving NK cell-based cancer immunotherapies.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Serological evidence of SARS-CoV-2 and co-infections in stray cats in Spain

  • Villanueva-Saz, S.
  • Giner, J.
  • Tobajas, A.P.
  • Pérez, M.D.
  • González-Ramírez, A.M.
  • Macías-León, J.
  • González, A.
  • Verde, M.
  • Yzuel, A.
  • Hurtado-Guerrero, R.
  • Pardo, J.
  • Santiago, L.
  • Paño-Pardo, J.R.
  • Ruíz, H.
  • Lacasta, D.M.
  • Sánchez, L.
  • Marteles, D.
  • Gracia, A.P.
  • Fernández, A.
A new coronavirus known as SARS-CoV-2 emerged in Wuhan in 2019 and spread rapidly to the rest of the world causing the pandemic disease named coronavirus disease of 2019 (COVID-19). Little information is known about the impact this virus can cause upon domestic and stray animals. The potential impact of SARS-CoV-2 has become of great interest in cats due to transmission among domestic cats and the severe phenotypes described recently in a domestic cat. In this context, there is a public health warning that needs to be investigated in relation with the epidemiological role of this virus in stray cats. Consequently, in order to know the impact of the possible transmission chain, blood samples were obtained from 114 stray cats in the city of Zaragoza (Spain) and tested for SARS-CoV-2 and other selected pathogens susceptible to immunosuppression including Toxoplasma gondii, Leishmania infantum, feline leukaemia virus (FeLV) and feline immunodeficiency virus (FIV) from January to October 2020. Four cats (3.51%), based on enzyme-linked immunosorbent assay (ELISA) using the receptor binding domain (RBD) of Spike antigen, were seroreactive to SARS-CoV-2. T. gondii, L. infantum, FeLV and FIV seroprevalence was 12.28%, 16.67%, 4.39% and 19.30%, respectively. Among seropositive cats to SARS-CoV-2, three cats were also seropositive to other pathogens including antibodies detected against T. gondii and FIV (n = 1); T. gondii (n = 1); and FIV and L. infantum (n = 1). The subjects giving positive for SARS-CoV-2 were captured in urban areas of the city in different months: January 2020 (2/4), February 2020 (1/4) and July 2020 (1/4). This study revealed, for the first time, the exposure of stray cats to SARS-CoV-2 in Spain and the existence of concomitant infections with other pathogens including T. gondii, L. infantum and FIV, suggesting that immunosuppressed animals might be especially susceptible to SARS-CoV-2 infection.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Preserved efficacy of lyophilized SARS-CoV-2 mRNA vaccine incorporating novel ionizable lipids after one year at 25 °C

  • Mata, Elena
  • Broset, Esther
  • Matute, Carlos
  • Stoian, Andrei
  • Adame, Susana
  • Alejo, Teresa
  • López, Alexandre
  • Andrés, Beatriz
  • Heredero, Juan
  • de Miguel, Diego
  • Giménez-Warren, Javier
  • Lampaya, Verónica
  • Casabona, Diego
  • Calvo, Alba
  • Quincoces, Gema
  • Peñuelas, Iván
  • Gamazo, Carlos
  • Uranga, Iratxe
  • Peña, Natacha
  • Arias, Maykel
  • Pardo, Julián
  • Moreno, Bernardino
  • Badiola, Juan
  • Martínez-Oliván, Juan
  • Pérez-Herrán, Esther
mRNA vaccines have shown great efficacy against SARS-CoV-2, yet challenges remain in optimizing vaccine components to achieve enhanced immune response and vaccine stability. In this study, we developed CPVax-CoV, a new lyophilized mRNA vaccine that features novel thiolactone-based ionizable lipids and newly designed untranslated regions (UTRs) for enhanced expression. Incorporation of these optimized components into our vaccine candidate CPVax-CoV significantly improved immune responses in mice compared to commercially available mRNA vaccines. Moreover, lyophilized CPVax-CoV has proven to be thermostable, maintaining its biological activity for up to one year at 4 °C and 25 °C after lyophilization, overcoming the cold-chain limitations of current mRNA vaccines. This vaccine demonstrates protective efficacy against ancestral SARS-CoV-2 and the Omicron XBB variant, offering a scalable solution for global distribution and pandemic preparedness. These findings underscore the potential of this platform for future next-generation mRNA vaccine development.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms

  • Pesini, Cecilia
  • Gil-Bellido, Mario
  • Millán, Lorena S.
  • Oñate, Carmen
  • Calvo-Pérez, Adanays
  • Santiago, Llipsy
  • Iglesias, Eldris
  • Bernal, Jorge Paúl
  • Araujo-Voces, Miguel
  • Paz Artigas, Laura
  • García-Martínez, Laura
  • Roig, Francisco J
  • Movilla Meno, Nieves
  • Garcia-Aznar, José Manuel
  • Menéndez-Jandula, Bárbara
  • Olave, María Teresa
  • Azaceta Reinares, Gemma
  • Garrote, Marta
  • Alvarez-Larrán, Alberto
  • Gálvez, Eva M
  • Sánchez Martínez, Diego
  • Arias, Maykel A
  • Pardo, Julian
  • Ramirez-Labrada, Ariel
Background The adoptive transfer of T cells engineered to express chimeric antigen receptors (CAR-T) has shown high efficacy and safety in treating various hematologic malignancies. However, many hematologic disorders, such as BCR::ABL1-negative myeloproliferative neoplasms (MPNs), lack effective treatment options. Some of these neoplasms are marked by a recurrent mutation that results in the expression of mutant calreticulin (mCALR), a neoantigen absent in healthy tissues, making it a highly specific and appealing target for CAR-T cell therapy. Methods Five distinct CARs were designed based on available monoclonal antibody sequences that target mCALR and were subsequently used to generate CAR-T cells. The most effective construct was selected through functional in vitro assays against mCALR-positive cell lines. Its efficacy was then evaluated in cell lines, patient-derived cells, and orthotopic xenograft models, assessing tumor burden, CAR-T cell infiltration, and animal survival. Bulk and single-cell RNA sequencing were performed on patient-derived cells and residual tumor cells from CART-treated mice, respectively, to investigate potential resistance mechanisms. The impact of the most relevant pathway alteration on CAR-T efficacy was also analyzed. Pharmacological rescue assays using targeted agents were then conducted. Results Among the five constructs, one demonstrated superior and specific cytotoxicity against mCALR-expressing cells, with no activity against mCALR-negative controls. This CAR-T cell also eliminated patient-derived MPN cells and controlled disease progression in xenograft models, which correlated with the persistence of CAR-T cells and tumor infiltration. Transcriptomic profiling of patient samples and residual tumor cells in spleens of treated mice revealed upregulation of anti-apoptotic proteins. Functional assays confirmed reduced CAR-T efficacy in Bcl-2 high cells, which was restored by co-treatment with venetoclax, indicating a viable combination approach to overcome resistance. Conclusions This study demonstrates, for the first time, the successful targeting of mCALR with CAR-T cells as a therapeutic strategy for MPNs. The chosen construct shows strong preclinical efficacy against established cell lines and patient-derived cells. Additionally, transcriptomic profiling uncovered apoptosis resistance mechanisms and supports a combination strategy with BH3 mimetics, such as venetoclax. These findings provide a compelling rationale for ongoing preclinical development and future clinical application of anti-mCALR CAR-T cells for the treatment of MPNs.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

How could antibiotics, probiotics, and corticoids modify microbiota and its influence in cancer immune checkpoint inhibitors: A review

  • Cruellas M.
  • Yubero A.
  • Zapata M.
  • Gálvez E.M.
  • Gascón M.
  • Isla D.
  • Lastra R.
  • Martínez-Lostao L.
  • Ozcáriz M.
  • Pardo, J.
  • Ramírez A.
  • Sesma A.
  • Torres-Ramón I.
  • Paño, J.R.
Immunotherapy has become a new paradigm in oncology, improving outcomes for several types of cancer. However, there are some aspects about its management that remain uncertain. One of the key points that needs better understanding is the interaction between immunotherapy and gut microbiome and how modulation of the microbiome might modify the efficacy of immunotherapy. Consequently, the negative impact of systemic antibiotics and corticosteroids on the efficacy of immunotherapy needs to be clarified.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Elevated interstitial fluid pressure promotes spheroid growth and reduces CAR-T therapeutic efficacy in solid tumors

  • Alamán-Díez, Pilar
  • Ferrer-Royo, Silvia
  • Oñate Salafranca, Carmen
  • Martín Compaired, Pablo
  • Balsas, Patricia
  • Pardo, Julián
  • García-Aznar, José Manuel
  • González-Loyola, Alejandra
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest solid tumors and is characterized by aggressive progression, a dense tumor microenvironment (TME), and resistance to conventional therapies. Among the barriers to effective treatments, the presence of elevated interstitial fluid pressure (IFP) may be important for drug penetration and immune cell infiltration. In this work, we present an innovative 3D microfluidic PDAC-on-a-chip that allows the application of IFP in a cell chamber to simulate the TME and evaluate the therapeutic efficacy of CAR-T cells engineered against the receptor EGFR expressed in tumor cells. Elevated IFP was associated with increased tumor spheroid growth, reduced caspase activation and decreased actin remodeling, indicating enhanced tumor resistance. CAR-T cells effectively targeted and eliminated tumor cells in 2D and 3D coculture models under normal pressure conditions. However, under high IFP, CAR-Tmediated cytotoxicity was impaired, indicating that some of the low efficacy of CAR-T cell therapy against solid tumors might be derived from IFP. These results highlight the importance of the mechanoenvironment in limiting the efficacy of current immunotherapies. Our model, which incorporates an IFP component, serves as a realistic preclinical platform for testing antitumor therapies in solid tumors. Statement of Significance: In this work, we present an innovative 3D pancreatic tumor-on-a-chip model that incorporates interstitial fluid pressure (IFP), which is a key mechanical component of solid tumors. Using this platform, we discovered that IFP enhances tumor proliferation whilst diminishing immunotherapy efficacy. This indicates the important role of mechanical pressure in limiting immune cell function in solid tumors. Our model is a valuable preclinical platform for investigating the efficacy of anti-tumor therapies and supports the development of strategies to overcome mechanical resistance and enhance therapy efficacy in solid tumors, such as pancreatic cancer.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Lytic IFNγ is stored in cytotoxic granules and coreleased with granzyme B to mediate cytotoxic T lymphocyte killing

  • Li, Xuemei
  • Schirra, Claudia
  • Wirkner, Marie-Louise
  • Tu, Szu-Min
  • Lin, Chin-Hsin
  • Hohmann, Meltem
  • Gu, Yuan
  • Santiago, Llipsy
  • Pardo, Julian
  • Arretxe, Iñaki
  • Alawar, Nadia
  • Chouaib, Abed Alrahman
  • Becherer, Ute
  • Lee, Po-Hsien
  • Hsu, Hao-Jen
  • Laschke, Matthias W.
  • Baldari, Cosima T.
  • Dustin, Michael L.
  • Rettig, Jens
  • Krause, Elmar
  • Chang, Hsin-Fang
Cytotoxic T lymphocytes (CTLs) eliminate target cells by forming immunological synapses and releasing effector molecules, including interferon gamma (IFNγ). However, how IFNγ contributes to cytotoxicity remains unclear. Here, we identify a subset of IFNγ stored within granzyme B⁺ cytotoxic granules (CGs) in activated mouse and human CTLs, which we term lytic IFNγ. This CG-associated IFNγ represents the primary pool released in a polarized manner at the immunological synapse together with canonical lytic molecules. Lytic IFNγ is present in tumor-infiltrating CTLs and is cosecreted with granzyme B (GzmB) in both soluble form and as part of supramolecular attack particles (SMAPs). Functional assays indicate that IFNγ contributes to CTL-mediated tumor cell death by acting in concert with granzyme B and perforin to increase cytotoxicity and promote apoptosis via the IFNγ–STAT1–caspase-3 pathway. CTLs lacking the vesicle priming factor Munc13-4 exhibit impaired release of both CGs and early-phase IFNγ. However, prolonged synapse engagement restores IFNγ secretion at distal membrane sites, revealing a second, nonpolarized IFNγ pool. Consistently, endogenous IFNγ is detected in both CG-enriched and multivesicular body (MVB)-enriched fractions. We propose that while lytic IFNγ is released from CGs at the synapse to directly promote target cell killing, nonpolarized IFNγ secretion originates from MVBs or small vesicles during sustained activation. Together, these findings reveal a previously unrecognized mechanism of IFNγ storage and release, establishing lytic IFNγ as a critical effector component of CTL cytotoxicity and antitumor immunity.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity

  • Marco, Sonia
  • Fernández, Myriam
  • Honorato, Beatriz
  • Juanarena, Nerea
  • Sainz, Cristina
  • Andueza, Ainhoa
  • Gould, David J.
  • Anderson, Seth
  • de Andrea, Carlos
  • Domínguez, Paulo Pérez
  • Wong, Paolo
  • Vásquez, Carlos
  • Narinda, Irene
  • Unzu, Carmen
  • Isola, Sergio
  • Tavira, Beatriz
  • Ariz, Mikel
  • Camps, Gracián
  • Sanmamed, Miguel F.
  • Pardo, Julián
  • Labiano, Sara
  • Alonso, Marta M.
  • Marco-Sanz, Javier
  • Guruceaga, Elizabeth
  • Collantes, María
  • Simón, Jon Ander
  • Peñuelas, Iván
  • Fernández-Irigoyen, Joaquín
  • Santamaría, Enrique
  • Prieto, Jesús
  • Dubrot, Juan
Radiotherapy (RT) can prime the immune system against cancer but often fails to generate effective antitumor responses due to concomitant induction of immunosuppressive factors. To overcome this limitation, we built upon the observation that RT enhances adeno-associated vectors (AAVs) tumor transduction through the epigenetic modification of vector episomes. We designed an AAV-based platform to deliver immunostimulatory cytokines through an interferon (IFN)-inducible promoter that allows for spatial control of transgene expression into irradiated tumors. As opposed to a constitutive system, local delivery of a vector encoding for inducible IL-12 (AAV-iIL12) achieves an efficient production of the cytokine without significant toxicity. Combination of RT and AAV-iIL12 generates a highly immunostimulatory tumor microenvironment (TME) leading to robust local and systemic antitumor responses in an IFNγ- and FAS-dependent manner, able to overcome common immune-evasion mechanisms. Our work shows that radiation coupled with AAV-based immune-gene delivery is an efficient and safe approach to treat cancer.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Circulating granzyme A is elevated within the dysregulated host response and associates with mortality in abdominal sepsis

  • Pellejero-Sagastizabal, Galadriel
  • Esteban, Patricia
  • Letona-Giménez, Santiago
  • Andrés-Tovar, Alejandro
  • Sierra, José Luis
  • Senan-Salinas, Ana
  • Galvez, Eva María
  • Pardo, Julián
  • Morte-Romea, Elena
  • Arias, Maykel
  • Paño-Pardo, José Ramón
Introduction Granzyme A (GzmA) has been identified as a key amplifier of sepsis-related inflammation in experimental models without contributing to pathogen clearance. However, its behavior and clinical relevance in human bacterial sepsis remain unknown. We aimed to characterize circulating GzmA in secondary peritonitis and explore its associations with clinical severity and all-cause mortality. Methods We conducted a single-center prospective cohort study of 42 adults with secondary peritonitis at Lozano Blesa Clinical Hospital (Zaragoza, Spain), with 31 healthy controls. Peripheral blood was obtained at baseline, 24 h, and 48 h. Serum GzmA concentration and activity, GzmB, cytokines, and endothelial and coagulation markers were measured. Analyses included comparisons across Sepsis-3 severity strata and exploratory prognostic models (logistic regression and receiver operating characteristic curves) evaluating associations between baseline biomarkers and mortality. Sensitivity analyses were performed after excluding patients meeting predefined immunosuppression criteria. Results At baseline, GzmA concentrations (2.3-fold, q-value = 5.41×10−12) and GzmA enzymatic activity (q-value = 6.75 × 10-³) were significantly higher in patients than controls, whereas GzmB did not differ (q-value = 0.332). Across baseline severity categories, VCAM-1 showed the clearest gradient (q-value = 0.017), while GzmA concentrations were numerically highest in septic shock (median 165.4 pg/mL). GzmA remained elevated through 48 h, and non-survivors had higher baseline levels than survivors. Each doubling of baseline GzmA was associated with higher overall in-hospital mortality (OR 2.52; 95% CI 1.11-5.75, p=0.028), with associations persisting after adjustment for age and comorbidity. Sensitivity analyses excluding immunosuppressed patients yielded a clearer association between GzmA and baseline severity, and confirmed its association with mortality. Discussion Circulating GzmA, but not GzmB, is markedly upregulated, remains elevated during early follow-up, and is preliminarily associated with mortality-related outcomes. These exploratory findings are consistent with experimental models and support further evaluations of extracellular GzmA to investigate its biological and potential translational relevance in sepsis.